

I hereby certify that this correspondence is being electronically filed in the United States Patent and Trademark Office on February 25, 2011.



Frank C. Eisenschenk, Ph.D., Patent Attorney

REQUEST FOR CERTIFICATE OF  
CORRECTION UNDER 37 CFR 1.322  
AND UNDER 37 CFR 1.323  
Docket No. TPL2900C3XC2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Mark Tawa, Orn Almarsson, Julius F. Remenar  
Issued : September 7, 2010  
Patent No. : 7,790,905  
Conf. No. : 2066  
For : Pharmaceutical Propylene Glycol Solvate Compositions

Mail Stop Certificate of Corrections Branch  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

REQUEST FOR CERTIFICATE OF CORRECTION  
UNDER 37 CFR 1.322 (OFFICE MISTAKE) AND  
UNDER 37 CFR 1.323 (APPLICANT MISTAKE)

Sir:

A Certificate of Correction for the above-identified patent has been prepared and is attached hereto.

In the left-hand column below is the column and line number where errors occurred in the patent. In the right-hand column is the page and line number in the application where the correct information appears or should appear.

**Patent Reads:**

Column 3, line 60:

“if their were”

**Application Should Read:**

Page 6, line 5:

--if there were--

Column 22, line 16:

“((<sup>8</sup>1995-2002, Materials Data, Inc.”

**Patent Reads:**

Column 22, line 63:

“(D 2001”

Column 24, line 24:

“gly solvate”

Column 27, Table 3, Column “API Chemical Name”, Row “(-)-amlodipine”:

“3-ethyl-S-methyl ester”

Column 30, Table 3, Column “Example of Indication”, Row “5-azacitidine”:

“Myelodysplastic”

Column 31, Table 3, Column “CAS No.”, Row “AC-5216”:

“2627-69-2”

Column 33, Table 3, Column “API Chemical Name”, Row “acrivastine + pseudoephedrine”:

“[S-(R\*,R)]-”

Column 33, Table 3, Column “API Chemical Name”, Row “Adenoscan”:

“6-Amino-9-β-D-nbofuranosyl-9H-purine [CAS]”

Page 38, lines 13-14:

--(<sup>8</sup>1995-2002, Materials Data, Inc.)--

**Application Reads:**

Page 39, line 20:

--© 2001--

Page 42, line 2:

--glycol solvate--

Page 48, Table 3, Column “API Chemical Name”, Row “(-)-amlodipine”:

--3-ethyl-5-methyl ester--

Page 50, Table 3, Column “Example of Indication”, Row “5-azacitidine”:

--Myelodysplastic--

Page 51, Table 3, Column “CAS No.”, Row “AC-5216”:

--blank--

Page 54, Table 3, Column “API Generic Name”, Row “acrivastine + pseudoephedrine”:

--[S-(R\*,R\*)]- --

Page 54, Table 3, Column “API Chemical Name”, Row “Adenoscan”:

--6-Amino-9-β-D-ribofuranosyl-9H-purine [CAS]--

Column 37, Table 3, Column "API Chemical Name", Row "alizapride":

"1H-Benzotriazole-5-carboxamide, 6-methoxy-N-[[1-(2-propenyl)-2-pyrrolidinyl)methyl]-[CAS]"

Column 37, Table 3, Column "API Chemical Name", Row "alprazolam":

"4H-[1,2,4]Triazolo[4,3-al][1,4]benzodiazepine"

Column 38, Table 3, Column "Example of Therapeutic Use", Row "alfuzosin":

"modified-release"

Column 39, Table 3, Column "API Generic Name",:

"Amdinocillin Pivoxil"

Column 40, Table 3, Column "Example of Indication", Row "AMD-3100":

"leucopenia"

Column 41, Table 3, Row "Aminoguanidine":

--API Chemical Name      CAS No.--  
79-17-4

Column 47, Table 3, Column "API Chemical Name", Row "aprepitant":

"5-[[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl)methyl]-1,2-dihydro- [CAS]"

Page 57, Table 3, Column "API Chemical Name", Row "alizapride":

--1H-Benzotriazole-5-carboxamide, 6-methoxy-N-[[1-(2-propenyl)-2-pyrrolidinyl)methyl]- [CAS]--

Page 58, Table 3, Column "API Chemical Name", Row "alprazolam":

--4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine--

Page 57, Table 3, Column "Example of Therapeutic Use", Row "alfuzosin":

--modified-release--

Page 60, Table 3, Column "API Generic Name",:

--Amdinocillin Pivoxil--

Page 60, Table 3, Column "Example of Indication", Row "AMD-3100":

--leucopenia--

Page 61, Table 3, Row "Aminoguanidine":

--API Chemical Name      CAS No.--  
79-17-4

Page 67, Table 3, Column "API Chemical Name", Row "aprepitant":

--5-[[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl)methyl]-1,2-dihydro- [CAS]--

Column 49, Table 3, Column “API Chemical Name”, Row “artemotil”:

“12+62,12aR\*)]-[CAS]”

Column 50, Table 3, Column “Example of Therapeutic Use”, Row “atenolol”:

“Antihypeertensive”

Column 52, Table 3, Column “Example of Indication”, Row “AZD-4282”:

“Pain, neuronpathic”

Column 53, Table 3, Column “API Generic Name”:

“aziocillin”

Column 53, Table 3, Column “API Chemical Name”, Row “balofloxacin”:

“3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[3-(methylamino)-1-pipendinyl]-4-oxo-[CAS]”

Column 53, Table 3, Column “API Generic Name”:

“bamidipine”

Column 57, Table 3, Column “API Chemical Name”, Row “betahistine”:

“2-Pyndineethanamine”

Column 58, Table 3, Column “Example of Therapeutic Use”, Row “benzydamine”:

“Stomatologic  
reproductive,  
inflammatory”

Page 69, Table 3, Column “API Chemical Name”, Row “artemotil”:

--12 $\beta$ ,12aR\*)]- [CAS]--

Page 71, Table 3, Column “Example of Therapeutic Use”, Row “atenolol”:

--Antihypertensive--

Page 73, Table 3, Column “Example of Indication”, Row “AZD-4282”:

--Pain, neuropathic--

Page 74, Table 3, Column “API Generic Name”:

--azlocillin--

Page 75, Table 3, Column “API Chemical Name”, Row “balofloxacin”:

--3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[3-(methylamino)-1-piperidiny]-4-oxo- [CAS]--

Page 75, Table 3, Column “API Generic Name”:

--barnidipine--

Page 79, Table 3, Column “API Chemical Name”, Row “betahistine”:

--2-Pyridineethanamine--

Page 78, Table 3, Column “Example of Therapeutic Use”, Row “benzydamine”:

--Stomatological,  
reproductive/gonoadal,  
anti-inflammatory--

Column 58, Table 3, Column “Example of Therapeutic Use”, Row “biapenem”:

“Beta-lactam antibiotic”

Column 59, Table 3, Column “API Generic Name”:

“Betamiverine”

Column 59, Table 3, Column “API Chemical Name”, Row “bimosiamose”:

“(1,1-Biphenyl)-3-acetic acid, 3',3'''-(1,6-hexanediyl)bis(6'-Alpha-D-mannopyranosyloxy)-, [CAS]”

Column 61, Table 3, Column “API Chemical Name”, Row “bosentan”:

“Benzenesulfonamide, 4-(1,1-dimethylethyl)-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)[2,2'-bipynmidin]-4-yl]-[CAS]”

Column 63, Table 3, Column “API Chemical Name”, Row “brivudin”:

“Uridine, 5-(2-bromoethenyl)-2-deoxy, (E)-[CAS]”

Column 66, Table 3, Row “bunazosin”:

“ <b>Example of Therapeutic Use</b> Antihypertens	<b>Example of Indication”</b>
--	-------------------------------

Column 67, Table 3, Column “API Generic Name”

“Calciuhi Mesoxalate”

Page 80, Table 3, Column “Example of Therapeutic Use”, Row “biapenem”:

--Beta-lactam antibiotic--

Page 80, Table 3, Column “API Generic Name”:

--Bietamiverine--

Page 81, Table 3, Column “API Chemical Name”, Row “bimosiamose”:

--(1,1'-Biphenyl)-3-acetic acid, 3',3'''-(1,6-hexanediyl)bis(6'-Alpha-D-mannopyranosyloxy)-, [CAS]--

Page 84, Table 3, Column “API Chemical Name”, Row “bosentan”:

--Benzenesulfonamide,4-(1,1-dimethylethyl)-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)[2,2'-bipyrimidin]-4-yl]-[CAS]--

Page 85, Table 3, Column “API Chemical Name”, Row “brivudin”:

--Uridine, 5-(2-bromoethenyl)-2'-deoxy, (E)-[CAS]--

Page 87, Table 3, Row “bunazosin”:

-- <b>Example of Therapeutic Use</b> Antihypertensive, adrenergic	<b>Example of Indication--</b> Hypertension, general
---	---

Page 90, Table 3, Column “API Generic Name”:

--Calcium Mesoxalate--

Column 69, Table 3, Column “API Chemical Name”, Row “camptothecin”:

“4-Ethyl-4-hydroxy-1H-pyrano-[13'4':6,7]indolizinol[1,2-b;]quinoline-3,14(4H,12H)-dione microemulsion”

Column 71, Table 3, Column “API Chemical Name”, Row “carmustine”:

“Urea, N,N-bis(2-chloroethyl)-N-nitroso-[CAS]”

Column 73, Table 3, Column “API Chemical Name”, Row “cefalexin”:

“5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[(aminophenylacetyl)amino]-3-methyl-oxo-, [CAS]”

Column 73, Table 3, Column “CAS No.”, Row “cefalexin”:

“8105879-42-3”

Column 75, Table 3, Column “API Chemical Name”, Row “cefmetazole”:

“5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[(cyanomethyl)thio]acetyl]amino]-7-methoxy-3-[[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-, (6R-cis)-[CAS]”

Column 75, Table 3, Column “API Chemical Name”, Row “cefonicid”:

“[6R-[6Alpha,7B(R)]]-[CAS]”

Page 91, Table 3, Column “API Chemical Name”, Row “camptothecin”:

--4-Ethyl-4-hydroxy-1H-pyrano-[13'4':6,7]indolizinol[1,2-b;]quinoline-3,14(4H,12H)-dione--

Page 94, Table 3, Column “API Chemical Name”, Row “carmustine”:

--Urea, N,N'-bis(2-chloroethyl)-N-nitroso-[CAS]--

Page 96, Table 3, Column “API Chemical Name”, Row “cefalexin”:

--5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[(aminophenylacetyl)amino]-3-methyl-8-oxo-, [CAS]--

Page 96, Table 3, Column “CAS No.”, Row “cefalexin”:

--105879-42-3--

Page 98, Table 3, Column “API Chemical Name”, Row “cefmetazole”:

--5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[(cyanomethyl)thio]acetyl]amino]-7-methoxy-3-[[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-, (6R-cis)-[CAS]--

Page 98, Table 3, Column “API Chemical Name”, Row “cefonicid”:

--[6R-[6Alpha,7β(R\*)]]-[CAS]--

Column 75, Table 3, Column “API Chemical Name”, Row “cefoperazone”:

“[6R-[6Alpha,7β(R\*)]]-[CAS]”

Column 75, Table 3, Column “API Chemical Name”, Row “cefpimizole”:

“[6R-[6Alpha,7β4R\*)]]-[CAS]”

Column 77, Table 3, Column “API Chemical Name”, Row “cefprome”:

“[6R-[6Alpha,711(Z)]]-[CAS]”

Column 77, Table 3, Column “API Chemical Name”, Row “cefuroxime axetil”:

“5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-[[[(aminocarbonyl)oxy]methyl]-7-[(2-furanyl(methoxyimino)acetyl]amino]-8-oxo-”

Column 78, Table 3, Column “Patent Reference”, Row “cefroxadine”:

“143511”

Column 78, Table 3, Column “Patent Reference”, Row “cefsulodin”:

“138765”

Column 78, Table 3, Column “Patent Reference”, Row “ceftazidime”:

“202539”

Column 81, Table 3, Column “API Generic Name”:

“Chlorproethazine”

Page 98, Table 3, Column “API Chemical Name”, Row “cefoperazone”:

--[6R-[6Alpha,7β(R\*)]]-[CAS]--

Page 100, Table 3, Column “API Chemical Name”, Row “cefpimizole”:

--[6R-[6Alpha,7β(R\*)]]-[CAS]--

Page 100, Table 3, Column “API Chemical Name”, Row “cefprome”:

--[6R-[6Alpha,7β(Z)]]-[CAS]--

Page 102, Table 3, Column “API Chemical Name”, Row “cefuroxime axetil”:

--5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-[[[(aminocarbonyl)oxy]methyl]-7-[[2-furanyl(methoxyimino)acetyl]amino]-8-oxo-,--

Page 101, Table 3, Column “Patent Reference”, Row “cefroxadine”:

--1435111--

Page 101, Table 3, Column “Patent Reference”, Row “cefsulodin”:

--1387656--

Page 101, Table 3, Column “Patent Reference”, Row “ceftazidime”:

--2025398--

Page 106, Table 3, Column “API Generic Name”:

--Chlorproethazine--

Column 81, Table 3, Column “API Generic Name”:

“Chlorquinaldol”

Column 83, Table 3, Column “API Chemical Name”, Row “choline-L-alfoscerate”:

“Ethanaminium, 2-[[[(2,3-dihydroxypropoxy) hydroxyphosphinyl]oxy]-N,N,N-trimethyl-,”

Column 85, Table 3, Column “API Generic Name”:

“cispiatin”

Column 89, Table 3, Column “API Chemical Name”, Row “CMI-392”:

“Trans-2-[3-methoxy-4-(2-p-chlorophenylthio)ethoxy-5-(N-methyl-N'-hydroxyureidyl)methylphenyl]-5-(3,4,5-trimethoxyphenyl)tetrahydrofuran”

Column 89, Table 3, Column “API Chemical Name”, Row “CMT-3”:

“(4a5,5aR,12a5)-[CAS]”

Column 89, Table 3, Column “API Chemical Name”, Row “CNI-1493”:

“Decanediamide, N,N-bis [3,5-bis[1-[(aminoiminomethyl)hydrazono] ethyl]phenyl]-, tetrahydrochloride [CAS]”

Column 90, Table 3, Column “Example of Indication”, Row “clopidogrel”:

“myocardia”

Page 106, Table 3, Column “API Generic Name”:

--Chlorquinaldol--

Page 107, Table 3, Column “API Chemical Name”, Row “choline-L-alfoscerate”:

--Ethanaminium, 2-[[[(2,3-dihydroxypropoxy) hydroxyphosphinyl]oxy]-N,N,N-trimethyl-,--

Page 110, Table 3, Column “API Generic Name”:

--cisplatin--

Page 115, Table 3, Column “API Chemical Name”, Row “CMI-392”:

--Trans-2-[3-methoxy-4-(2-p-chlorophenylthio)ethoxy-5-(N'-methyl-N'-hydroxyureidyl)methylphenyl]-5-(3,4,5-trimethoxyphenyl)tetrahydrofuran--

Page 115, Table 3, Column “API Chemical Name”, Row “CMT-3”:

--(4aS,5aR,12aS)- [CAS]--

Page 115, Table 3, Column “API Chemical Name”, Row “CNI-1493”:

--Decanediamide, N,N'-bis [3,5-bis[1-[(aminoiminomethyl)hydrazono] ethyl]phenyl]-, tetrahydrochloride [CAS]--

Page 114, Table 3, Column “Example of Indication”, Row “clopidogrel”:

--myocardial--



Column 91, Table 3, Column “API Chemical Name”, Row “CNS-5161”:

“N-[2-chloro-5-(methylthio)phenyl]-N-methyl-N-[3-(methylthio)phenyl]guanidine [CAS]”

Column 92, Table 3, Row “CP-461”:

<b>“Example of Therapeutic Use</b> Anticancer, other	<b>Example of Indication”</b>
---	-------------------------------

Column 92, Table 3, Row “CRL-5861”:

<b>“Example of Therapeutic Use</b> Antisickling	<b>Example of Indication”</b>
--	-------------------------------

Column 95, Table 3, Column “API Chemical Name”, Row “cymserine”:

“(3aS,8aR)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-yl ester [CAS]”

Column 95, Table 3, Column “API Chemical Name”, Row “cyproterone”:

“(1 $\beta$ ,2 $\beta$ )-6-Chloro-1,2-dihydro-17-hydroxy-3H-cyclopropa[1,2]pregna-1,4,6-triene-3,20-dione [CAS]”

Column 95, Table 3, Column “API Chemical Name”, Row “dalfoprstin + quinupristin”:

“mixt with 4-(4-(dimethylamino)-N-methyl-L-phenylalanine)-5-(5-((1-azabicyclo(2.2.2)oct-3-ylthio)methyl)-4-oxo-L-2-pipendinecarboxylic acid) virginiamycin S1- [CAS]”

Page 115, Table 3, Column “API Chemical Name”, Row “CNS-5161”:

--N'-[2-chloro-5-(methylthio)phenyl]-N-methyl-N-[3-(methylthio)phenyl]guanidine [CAS]--

Page 117, Table 3, Row “CP-461”:

<b>--Example of Therapeutic Use</b> Anticancer, other	<b>Example of Indication--</b> Cancer, prostate
--	--

Page 117, Table 3, Row “CRL-5861”:

<b>--Example of Therapeutic Use</b> Antisickling	<b>Example of Indication--</b> Anaemia, sickle cell
---	--

Page 120, Table 3, Column “API Chemical Name”, Row “cymserine”:

--(3aS,8aR)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-yl ester [CAS]--

Page 120, Table 3, Column “API Chemical Name”, Row “cyproterone”:

--(1 $\beta$ ,2 $\beta$ )-6-Chloro-1,2-dihydro-17-hydroxy-3'H-cyclopropa[1,2]pregna-1,4,6-triene-3,20-dione [CAS]--

Page 122, Table 3, Column “API Chemical Name”, Row “dalfoprstin + quinupristin”:

--mixt with 4-(4-(dimethylamino)-N-methyl-L-phenylalanine)-5-(5-((1-azabicyclo(2.2.2)oct-3-ylthio)methyl)-4-oxo-L-2-piperidinecarboxylic acid) virginiamycin S1- [CAS]--

Column 97, Table 3, Row “DB-67”:

<b>“API Generic Name</b>	<b>API Chemical Name”</b>
DB-67	7-tert-Butyldimethylsilyl-10-hydroxy-camptothecin

Page 123, Table 3, Row “DB-67”:

<b>--API Generic Name</b>	<b>API Chemical Name--</b>
DB-67	7-tert-Butyldimethylsilyl-10-hydroxycamptothecin

Column 99, Table 3, Column “API Generic Name”:

“Delmadinane”

Page 124, Table 3, Column “API Generic Name”:

--Delmadinone--

Column 100, Table 3, Row “dersalazine”:

<b>“Example of Therapeutic Use</b>	<b>Example of Indication”</b>
Anti-inflammatory	

Page 125, Table 3, Row “dersalazine”:

<b>--Example of Therapeutic Use</b>	<b>Example of Indication--</b>
Anti-inflammatory	Colitis, ulcerative

Column 101, Table 3, Column “API Chemical Name”, Row “dexrazoxane”:

“2,6-Piperazinedione, 4,4'-(1-methyl-1,2-ethanediyl)bis-, (5)- [CAS]”

Page 127, Table 3, Column “API Chemical Name”, Row “dexrazoxane”:

--2,6-Piperazinedione, 4,4'-(1-methyl-1,2-ethanediyl)bis-, (S)- [CAS]--

Column 101, Table 3, Column “API Chemical Name”, Row “dextropropoxyphene”:

“[S-(R,S\*)]-[CAS]”

Page 128, Table 3, Column “API Chemical Name”, Row “dextropropoxyphene”:

--[S-(R\*,S\*)]- [CAS]--

Column 101, Table 3, Column “API Chemical Name”, Row “dibekacin”:

“D-Streptamine, O-3-amino-3-deoxy-Alpha-D-glucopyranosyl-(1-6)-O-[2,6-diamino-2,3,4,6-tetradeoxy-Alpha-D-erythro-hexopyranosyl-(1-4)]-2-deoxy-, sulfate (salt)[CAS]”

Page 128, Table 3, Column “API Chemical Name”, Row “dibekacin”:

--D-Streptamine, O-3-amino-3-deoxy-Alpha-D-glucopyranosyl-(1-6)-O-[2,6-diamino-2,3,4,6-tetradeoxy-Alpha-D-erythro-hexopyranosyl-(1-4)]-2-deoxy-, sulfate (salt)[CAS]--

Column 105, Table 3, Column “API Generic Name”:

“Diisopropylamine”

Page 131, Table 3, Column “API Generic Name”:

--Diisopropylamine--

Column 105, Table 3, Column “API Chemical Name”, Row “dinoprostone”:

“Prosta-5,13-dien-1-oic acid, 11,15-dihydroxy-9-oxo-, (5Z, 11 Alpha, 13E, 15S)-[CAS]”

Column 105, Table 3, Column “API Generic Name”:

“Dioxethednne”

Column 107, Table 3, Column “API Generic Name”:

“Dastigmine”

Column 107, Table 3, Column “API Chemical Name”, Row “DK-507k”:

“(–)-7-[(7S)-7-Amino-5-azaspiro[2,4]heptan-5-yl]-6-fluoro-1-[(1R,2S)-2-fluoro-1-cyclopropyl]-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid hydrochloride monohydrate”

Column 107, Table 3, Column “API Chemical Name”, Row “dofetilide”:

“Methanesulfonamide, N-[4-[2-[methyl[2-[4-[(methylsulfonyl)amino]phenoxy]ethyl]amino]ethyl]phenyl]-[CAS]”

Column 108, Table 3, Column “Example of Therapeutic Use”, Row “docusate”:

“Formulation, derm”

Column 109, Table 3, Column “API Generic Name”:

“Domiodoi”

Page 132, Table 3, Column “API Chemical Name”, Row “dinoprostone”:

--Prosta-5,13-dien-1-oic acid, 11,15-dihydroxy-9-oxo-, (5Z,11Alpha,13E,15S)-[CAS]--

Page 132, Table 3, Column “API Generic Name”:

--Dioxethedrine--

Page 133, Table 3, Column “API Generic Name”:

--Distigmine--

Page 133, Table 3, Column “API Chemical Name”, Row “DK-507k”:

--(–)-7-[(7S)-7-Amino-5-azaspiro[2,4]heptan-5-yl]-6-fluoro-1-[(1R,2S)-2-fluoro-1-cyclopropyl]-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid hydrochloride monohydrate--

Page 134, Table 3, Column “API Chemical Name”, Row “dofetilide”:

--Methanesulfonamide, N-[4-[2-[methyl[2-[4-[(methylsulfonyl)amino]phenoxy]ethyl]amino]ethyl]phenyl]- [CAS]--

Page 134, Table 3, Column “Example of Therapeutic Use”, Row “docusate”:

--Formulation, dermal, topical--

Page 134, Table 3, Column “API Generic Name”:

--Domiodol--

Column 109, Table 3, Column “API Generic Name”:

“darzolamide”

Column 109, Table 3, Column “API Chemical Name”, Row “dorzolamide + timolol”:

“4H-Thieno(2,3-b)thiopyran-2-sulfonamide, 4-(ethylamino)-5,6-dihydro-6-methyl-7,7-dioxide (4S-trans) + ethyl 2-propanol, 1-[(1,1-dimethylamino)-3-[[4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl]oxy]-, (5), (Z)-2-butenedioate (1:1) (salt) [CAS]”

Column 113, Table 3, Column “API Chemical Name”, Row “E-1010”:

“1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 6-[(1R)-1-hydroxyethyl]-3-[[[(3S,5S)-5-[(R)-hydroxy(3R)-3-pyrrolidinylmethyl]-3-pyrrolidinyl]thio]-4-methyl-7-oxo-, monohydrochloride, (4R,5S,6S)-[CAS]”

Column 113, Table 3, Column “API Chemical Name”, Row “E-2101”:

“N-Ethyl-(1-[1-(2-fluorophenethyl)piperidin-4-yl]-1H-indol-6-yl)acetamide”

Column 113, Table 3, Column “API Chemical Name”, Row “E-5842”:

“Pyridine, 4-(4-fluorophenyl)-1,2,3,6-tetrahydro-1-[4-(1H-1,2,4-triazol-1-yl)butyl]-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) [CAS]”

Column 115, Table 3, Column “API Generic Name”:

“Edetate Galcium Disodium”

Page 135, Table 3, Column “API Generic Name”:

--dorzolamide--

Page 135, Table 3, Column “API Chemical Name”, Row “dorzolamide + timolol”:

--4H-Thieno(2,3-b)thiopyran-2-sulfonamide, 4-(ethylamino)-5,6-dihydro-6-methyl-7,7-dioxide (4S-trans) + ethyl 2-propanol, 1-[(1,1-dimethylamino)-3-[[4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl]oxy]-, (S), (Z)-2-butenedioate (1:1) (salt) [CAS]--

Page 139, Table 3, Column “API Chemical Name”, Row “E-1010”:

--1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 6-[(1R)-1-hydroxyethyl]-3-[[[(3S,5S)-5-[(R)-hydroxy(3R)-3-pyrrolidinylmethyl]-3-pyrrolidinyl]thio]-4-methyl-7-oxo-, monohydrochloride, (4R,5S,6S)- [CAS]--

Page 139, Table 3, Column “API Chemical Name”, Row “E-2101”:

--N-Ethyl-(1-[1-(2-fluorophenethyl)piperidin-4-yl]-1H-indol-6-yl)acetamide--

Page 140, Table 3, Column “API Chemical Name”, Row “E-5842”:

--Pyridine, 4-(4-fluorophenyl)-1,2,3,6-tetrahydro-1-[4-(1H-1,2,4-triazol-1-yl)butyl]-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) [CAS]--

Page 141, Table 3, Column “API Generic Name”:

--Edetate Calcium Disodium--

Column 116, Table 3, Column “Example of Therapeutic Use”, Row “eflucimibe”:

“Hypolipaemic/Antitherosclerosis”

Column 118, Table 3, Column “Example of Therapeutic Use”, Row “enoxacin”:

“Quinolone antibacter”

Column 119, Table 3, Column “API Chemical Name”, Row “eperisone”:

“1-Propanone, 1-(4-ethylphenyl)-2-methyl-3-(1-pipendinyl)- [CAS]”

Column 119, Table 3, Column “API Generic Name”:

“Epiclilin”

Column 119, Table 3, Column “API Generic Name”:

“Epinzole”

Column 119, Table 3, Row “Epitiostanol”:

<b>“API Chemical Name</b>	<b>CAS No.”</b>
2363-58-8	

Column 119, Table 3, Column “API Chemical Name”, Row “eptaplatin”:

“Platinum, [(4R,5R)-2-(1-methylethyl)-1,3-dioxolane-4,5-dimethanamine-kappaN4',kappaN5][propanedioato(2-)-kappaO1,kappaO3]-, (SP-4-2)-[CAS]”

Page 142, Table 3, Column “Example of Therapeutic Use”, Row “eflucimibe”:

--Hypolipaemic/Antiatherosclerosis--

Page 145, Table 3, Column “Example of Therapeutic Use”, Row “enoxacin”:

--Quinolone antibacterial--

Page 146, Table 3, Column “API Chemical Name”, Row “eperisone”:

--1-Propanone, 1-(4-ethylphenyl)-2-methyl-3-(1-piperidiny)- [CAS]--

Page 146, Table 3, Column “API Generic Name”:

--Epicillin--

Page 146, Table 3, Column “API Generic Name”:

--Epirizole--

Page 146, Table 3, Row “Epitiostanol”:

<b>--API Chemical Name</b>	<b>CAS No.--</b>
	2363-58-8

Page 147, Table 3, Column “API Chemical Name”, Row “eptaplatin”:

--Platinum, [(4R,5R)-2-(1-methylethyl)-1,3-dioxolane-4,5-dimethanamine-kappaN4,kappaN5][propanedioato(2-)-kappaO1,kappaO3]-, (SP-4-2)- [CAS]--

Column 119, Table 3, Row “Eptastigmine”:

**“API Chemical                      CAS No.”**  
**Name**  
 101246-68-8

Page 147, Table 3, Row “Eptastigmine”:

**--API Chemical                      CAS No.--**  
**Name**  
 101246-68-8

Column 121, Table 3, Column “API Chemical Name”, Row “escitalopram”:

“(5)- [CAS]”

Page 148, Table 3, Column “API Chemical Name”, Row “escitalopram”:

“(S)- [CAS]--”

Column 121, Table 3, Column “API Generic Name”:

“Etafedrine”

Page 149, Table 3, Column “API Generic Name”:

“--Etafedrine--”

Column 123, Table 3, Column “API Generic Name”:

“Etilefnn”

Page 151, Table 3, Column “API Generic Name”:

“--Etilefrin--”

Column 125, Table 3, Column “API Chemical Name”, Row “exatecan”:

“10H,13H-Benzo[de]pyrano[3',4':6,7]indolizino  
 [1,2-b]quinoline-10,13-diane, 1-amino-9-ethyl-  
 5-fluoro-1,2,3,9,12,15-hexahydro-9-hydroxy-4-  
 methyl-, (1S,9S)-, [CAS]”

Page 153, Table 3, Column “API Chemical Name”, Row “exatecan”:

--10H,13H-Benzo[de]pyrano[3',4':6,7]  
 indolizino[1,2-b]quinoline-10,13-dione, 1-  
 amino-9-ethyl-5-fluoro-1,2,3,9,12,15-  
 hexahydro-9-hydroxy-4-methyl-, (1S,9S)-,  
 [CAS]--”

Column 125, Table 3, Column “API Chemical Name”, Row “exemestane”:

“Androsta-1,4-diene-3,17-diane, 6-methylene-  
 [CAS]”

Page 153, Table 3, Column “API Chemical Name”, Row “exemestane”:

--Androsta-1,4-diene-3,17-dione,  
 6-methylene- [CAS]--”

Column 125, Table 3, Column “API Chemical Name”, Row “ezetimibe”:

“2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-  
 fluorophenyl)-3-hydroxypropyl]-4-(4-  
 hydroxyphenyl)-, (3R,4S)-[CAS]”

Page 153, Table 3, Column “API Chemical Name”, Row “ezetimibe”:

--2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-  
 3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-  
 hydroxyphenyl)-, (3R,4S)- [CAS]--”

Column 129, Table 3, Column “API Generic Name”:

“Ferrous Gluconate”

Column 129, Table 3, Column “API Chemical Name”, Row “ferumoxytol”:

“Polyglucose sorbitol carboxymethyl ether-coated non-stoichiometric magnetite Imaging agent”

Column 129, Table 3, Column “API Chemical Name”, Row “fexofenadine”:

“Benzeneacetic acid, 4-[1-hydroxy-4-[4(hydroxydiphenylmethyl)-1-pipendinyl]butyl]-Alpha,Alpha-dimethyl-, [CAS]”

Column 129, Table 3, Column “API Chemical Name”, Row “fidarestat”:

“Spiro(4H-1-benzopyran-4,4-imidazolidine)-2-carboxamide, 6-fluoro-2,3-dihydro-2',5'-dioxo-, (2S-cis)-, [CAS]”

Column 131, Table 3, Column “API Generic Name”:

“Fludeoxyglucose F1B”

Column 131, Table 3, Column “API Chemical Name”, Row “flurbiprofen”:

“[1,1-Biphenyl]-4-acetic acid, 2-fluoro-Alpha-methyl-[CAS]”

Page 156, Table 3, Column “API Generic Name”:

--Ferrous Gluconate--

Page 157, Table 3, Column “API Chemical Name”, Row “ferumoxytol”:

--Polyglucose sorbitol carboxymethyl ether-coated non-stoichiometric magnetite--

Page 157, Table 3, Column “API Chemical Name”, Row “fexofenadine”:

--Benzeneacetic acid, 4-[1-hydroxy-4-[4(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-Alpha,Alpha-dimethyl-, [CAS]--

Page 157, Table 3, Column “API Chemical Name”, Row “fidarestat”:

--Spiro(4H-1-benzopyran-4,4'-imidazolidine)-2-carboxamide, 6-fluoro-2,3-dihydro-2',5'-dioxo-, (2S-cis)-, [CAS]--

Page 159, Table 3, Column “API Generic Name”:

--Fludeoxyglucose F18--

Page 160, Table 3, Column “API Chemical Name”, Row “flurbiprofen”:

--[1,1'-Biphenyl]-4-acetic acid, 2-fluoro-Alpha-methyl- [CAS]--

Column 133, Table 3, Column “API Chemical Name”, Row “flutazolan”:

“Oxazolo[3,2-d][1,4]benzodiazepin-6(SH)-one, 10-chloro-11b-(2-fluorophenyl)-2,3,7,11b-tetrahydro-7-(2-hydroxyethyl)-[CAS]”

Column 135, Table 3, Column “API Chemical Name”, Row “fumagiline”:

“[3R-(3Alpha,4Alpha(2R\*,3R\*),5β,6β(all-E))]--[CAS]”

Column 137, Table 3, Column “API Generic Name”:

“Gepef rifle”

Column 138, Table 3, Column “Example of Therapeutic Use”, Row “gallium nitrate”:

“Osteoporosh”

Column 139, Table 3, Column “API Chemical Name”, Row “gimatecan”:

“dimethylethoxy)imino]methyl]-4-ethyl-4-hydroxy-1-12-dihydro-14H-pyrano[3,4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione”

Column 139, Table 3, Column “API Generic Name”:

“Giyburide”

Column 141, Table 3, Column “API Generic Name”:

“griseofuivin”

Page 160, Table 3, Column “API Chemical Name”, Row “flutazolan”:

--Oxazolo[3,2-d][1,4]benzodiazepin-6(5H)-one, 10-chloro-11b-(2-fluorophenyl)-2,3,7,11b-tetrahydro-7-(2-hydroxyethyl)-[CAS]--

Page 164, Table 3, Column “API Chemical Name”, Row “fumagiline”:

--[3R-[3Alpha,4Alpha(2R\*,3R\*),5β,6β(all-E))]--[CAS]--

Page 167, Table 3, Column “API Generic Name”:

--Gepefrine--

Page 165, Table 3, Column “Example of Therapeutic Use”, Row “gallium nitrate”:

--Osteoporosis treatment--

Page 167, Table 3, Column “API Chemical Name”, Row “gimatecan”:

--(4S)-11-[(E)-[(1,1-dimethylethoxy)imino]methyl]-4-ethyl-4-hydroxy-1-12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione--

Page 169, Table 3, Column “API Generic Name”:

--Glyburide--

Page 170, Table 3, Column “API Generic Name”:

--griseofulvin--



Column 141, Table 3, Column “API Chemical Name”, Row “GYKI-16084”:

“(+) -R-2-{3-[N-(2-Benzo[1,4]dioxanylmethyl)amino]-1-propyl}-3(2H)-pyndazinone hydrochloride”

Column 143, Table 3, Column “API Generic Name”:

“HGP-6”

Column 145, Table 3, Column “API Generic Name”:

“Hydroxychloroquine”

Column 145, Table 3, Column “API Chemical Name”, Row “hyoscyamine”:

“benzeneacetic acid, Alpha(hydroxymethyl)-, 8-methyl-B-azabicyclo [3.2.1.]oct-3-yl ester, [3(S)-endo],”

Column 145, Table 3, Column “API Chemical Name”, Row “ibopamine”:

“Propanoic acid, 2-methyl-, 4-12-(methylamino)ethyl]-1,2-phenylene ester-[CAS]”

Column 147, Table 3, Column “API Chemical Name”, Row “indeloxazine”:

“Morptioline”

Page 171, Table 3, Column “API Chemical Name”, Row “GYKI-16084”:

--(+)-R-2-{3-[N-(2-Benzo[1,4]dioxanylmethyl)amino]-1-propyl}-3(2H)-pyridazinone hydrochloride--

Page 172, Table 3, Column “API Generic Name”:

--HGP-6^--

Page 174, Table 3, Column “API Generic Name”:

--Hydroxychloroquine--

Page 174, Table 3, Column “API Chemical Name”, Row “hyoscyamine”:

--benzeneacetic acid, Alpha(hydroxymethyl)-, 8-methyl-8-azabicyclo [3.2.1.]oct-3-yl ester, [3(S)-endo],--

Page 175, Table 3, Column “API Chemical Name”, Row “ibopamine”:

--Propanoic acid, 2-methyl-, 4-[2-(methylamino)ethyl]-1,2-phenylene ester-[CAS]--

Page 178, Table 3, Column “API Chemical Name”, Row “indeloxazine”:

--Morpholine--

Column 149, Table 3, Column “API Chemical Name”, Row “indinavir”:

“D-erythro-Pentonamide, 2,3,5-trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl), [1S-[1Alpha(R\*),2Alpha]]-, [CAS]”

Column 149, Table 3, Column “API Chemical Name”, Row “indisulam”:

“1,4-Benzenedisulfonamide, N-(3-chloro-1H-indol-7-yl)-[CAS]”

Column 151, Table 3, Column “API Chemical Name”, Row “irofulven”:

“Spiro[cyclopropane-1,5-[5H]inden]-7'(6H)-one, 6'-hydroxy-2',4',6'-trimethyl-, (R)-[CAS]”

Column 151, Table 3, Column “API Chemical Name”, Row “isepamicin”:

“D-Streptamine, O-6-amino-6-deoxy-Alpha-D-glucopyranosyl-(1-4)-O-[3-deoxy-4-C-methyl-3-(methylamino)-β-L-arabinopyranosyl-(1-6)]-N1-(3-amino-2-hydroxy-1-oxopropyl)-2-deoxy-, (S)- [CAS]”

Column 152, Table 3, Column “Example of Indication”, Row “isepamicin”:

“Infection, fungal, general”

Page 179, Table 3, Column “API Chemical Name”, Row “indinavir”:

--D-erythro-Pentonamide, 2,3,5-trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl), [1S-[1Alpha(R\*),2Alpha]]-, [CAS]--

Page 179, Table 3, Column “API Chemical Name”, Row “indisulam”:

--1,4-Benzenedisulfonamide, N-(3-chloro-1H-indol-7-yl)- [CAS]--

Page 181, Table 3, Column “API Chemical Name”, Row “irofulven”:

--Spiro[cyclopropane-1,5'-[5H]inden]-7'(6H)-one, 6'-hydroxy-2',4',6'-trimethyl-, (R)- [CAS]--

Page 182, Table 3, Column “API Chemical Name”, Row “isepamicin”:

--D-Streptamine, O-6-amino-6-deoxy-Alpha-D-glucopyranosyl-(1-4)-O-[3-deoxy-4-C-methyl-3-(methylamino)-β-L-arabinopyranosyl-(1-6)]-N1-(3-amino-2-hydroxy-1-oxopropyl)-2-deoxy-, (S)- [CAS]--

Page 182, Table 3, Column “Example of Indication”, Row “isepamicin”:

--Infection, dermatological--

Column 153, Table 3, Column “API Chemical Name”, Row “israpafant”:

“6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine, 4-(2-chlorophenyl)-6,9-dimethyl-2-[2-[4-(2-methylpropyl)phenyl]ethyl]-[CAS]”

Column 155, Table 3, Column “API Chemical Name”, Row “JTV-519”:

“1,4-Benzothiazepine, 2,3,4,5-tetrahydro-7-methoxy-4-[1-oxo-3-[4-(phenylmethyl)-1-piperidinylpropyl]- [CAS]”

Column 155, Table 3, Column “API Chemical Name”, Row “KCB-328”:

“Methanesulfonamide, N-[3-amino-4-[2-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]ethoxy]phenyl]-, monohydrochloride [CAS]”

Column 157, Table 3, Column “API Generic Name”:

“KUL7211”

Column 157, Table 3, Column “API Chemical Name”, Row “L-758298”:

“Phosphonic acid, [3-fl(2R,3S)-2-((1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]-[CAS]”

Column 157, Table 3, Column “API Chemical Name”, Row “landiolol”:

“Benzenepropanoic acid, 4-[2-hydroxy-3-morpholinylcarbonyl]amino]ethyl]amino]propoxy]-,”

Page 183, Table 3, Column “API Chemical Name”, Row “israpafant”:

--6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine, 4-(2-chlorophenyl)-6,9-dimethyl-2-[2-[4-(2-methylpropyl)phenyl]ethyl]-[CAS]--

Page 185, Table 3, Column “API Chemical Name”, Row “JTV-519”:

--1,4-Benzothiazepine, 2,3,4,5-tetrahydro-7-methoxy-4-[1-oxo-3-[4-(phenylmethyl)-1-piperidinylpropyl]- [CAS]--

Page 185, Table 3, Column “API Chemical Name”, Row “KCB-328”:

--Methanesulfonamide, N-[3-amino-4-[2-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]ethoxy]phenyl]-, monohydrochloride [CAS]--

Page 187, Table 3, Column “API Generic Name”:

--KUL-7211--

Page 188, Table 3, Column “API Chemical Name”, Row “L-758298 ”:

--Phosphonic acid, [3-[[2-(2R,3S)-2-((1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]-[CAS]--

Page 188, Table 3, Column “API Chemical Name”, Row “landiolol ”:

--Benzenepropanoic acid, 4-[2-hydroxy-3-[[2-[(4-morpholinylcarbonyl)amino]ethyl]amino]propoxy]-,--

Column 157, Table 3, Column “API Chemical Name”, Row “laniquidar”:

“Methyl 6,11-dihydro-11-11-[2-[4-(-2-quinolylmethoxy)phenyl]ethyl]-4-piperidinylidene]-5H-imidazo[2,1-b][3]benzazepine-3-carboxylate”

Column 159, Table 3, Column “API Chemical Name”, Row “lasofoxifene”:

“2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-(4-(2-(1-pyrrolidinyl)ethoxy)phenyl)-(5R-cis)-, (5-(R\*, R\*))-2,3-dihydroxybutanedioate [CAS]”

Column 159, Table 3, Column “API Chemical Name”, Row “levamisole”:

“Imidazo[2,1-b]thiazole, 2,3,5,6-tetrahydro-6-phenyl-, (5)-[CAS]”

Column 160, Table 3, Column “Example of Therapeutic Use”, Row “LAX-111”:

“Neuroleptic”

Column 161, Table 3, Column “API Chemical Name”, Row “levetiracetam”:

“1-Pyrrolidineacetamide, Alpha-ethyl-2-oxo-, (5)-[CAS]”

Column 161, Table 3, Column “API Chemical Name”, Row “levobupivacaine”:

“2-Piperidinecarboxamide, 1-butyl-N-(2,6-dimethylphenyl)-, (5)-[CAS]”

Page 189, Table 3, Column “API Chemical Name”, Row “laniquidar”:

--Methyl 6,11-dihydro-11-[1-[2-[4-(-2-quinolylmethoxy)phenyl]ethyl]-4-piperidinylidene]-5H-imidazo[2,1-b][3]benzazepine-3-carboxylate--

Page 189, Table 3, Column “API Chemical Name”, Row “lasofoxifene”:

--2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-(4-(2-(1-pyrrolidinyl)ethoxy)phenyl)-(5R-cis)-, (S-(R\*, R\*))-2,3-dihydroxybutanedioate [CAS]--

Page 191, Table 3, Column “API Chemical Name”, Row “levamisole”:

--Imidazo[2,1-b]thiazole, 2,3,5,6-tetrahydro-6-phenyl-, (S)- [CAS]--

Page 190, Table 3, Column “Example of Therapeutic Use”, Row “LAX-111”:

--Neuroleptic--

Page 191, Table 3, Column “API Chemical Name”, Row “levetiracetam”:

--1-Pyrrolidineacetamide, Alpha-ethyl-2-oxo-, (S)- [CAS]--

Page 192, Table 3, Column “API Chemical Name”, Row “levobupivacaine”:

--2-Piperidinecarboxamide, 1-butyl-N-(2,6-dimethylphenyl)-, (S)- [CAS]--

Column 161, Table 3, Column “API Chemical Name”, Row “levodropropizine”:

“1,2-Propanediol, 3-(4-phenyl-1-piperazinyl)-, (5)-[CAS]”

Column 161, Table 3, Column “API Chemical Name”, Row “levofloxacin”:

“7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, (5)-[CAS]”

Column 161, Table 3, Column “API Chemical Name”, Row “levomoprolol”:

“2-Propanol, 1-(2-methoxyphenoxy)-3-[(1-methylethyl)amino]-, (5)-[CAS]”

Column 161, Table 3, Column “API Chemical Name”, Row “levosimendan”:

“Propanedinitrile, (14-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]-, (R)- [CAS]”

Column 163, Table 3, Column “API Chemical Name”, Row “liranaftate”:

“Garbamothioic acid”

Column 163, Table 3, Column “API Chemical Name”, Row “lisinopril”:

“(5)- [CAS]”

Column 163, Table 3, Column “API Chemical Name”, Row “LLUAlpha”:

“S-2,7,8-Trimethyl-6-(11-carboxyethyl)-6-hydroxychroman”

Page 192, Table 3, Column “API Chemical Name”, Row “levodropropizine”:

--1,2-Propanediol, 3-(4-phenyl-1-piperazinyl)-, (S)- [CAS]--

Page 192, Table 3, Column “API Chemical Name”, Row “levofloxacin”:

--7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, (S)- [CAS]--

Page 192, Table 3, Column “API Chemical Name”, Row “levomoprolol”:

--2-Propanol, 1-(2-methoxyphenoxy)-3-[(1-methylethyl)amino]-, (S)- [CAS]--

Page 193, Table 3, Column “API Chemical Name”, Row “levosimendan”:

--Propanedinitrile, [[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]-, (R)- [CAS]--

Page 194, Table 3, Column “API Chemical Name”, Row “liranaftate”:

--Carbamothioic acid--

Page 194, Table 3, Column “API Chemical Name”, Row “lisinopril”:

--(S)- [CAS]--

Page 195, Table 3, Column “API Chemical Name”, Row “LLUAlpha”:

--S-2,7,8-Trimethyl-6-(β-carboxyethyl)-6-hydroxychroman--

Column 164, Table 3, Row “lobaplatin”:

<b>“Example of Therapeutic Use</b>	<b>Example of Indication</b>
Anticancer alkylatin	

Column 165, Table 3, Column “API Chemical Name”, Row “loratadine”:

“1-Pipendinecarboxylic acid”

Column 167, Table 3, Column “API Chemical Name”, Row “lurtotecan”:

“11H-1,4-Dioxino[2,3-g]pyrano[3,4:6,7]indolizino[1,2-b]quinoline-9,12[8H,14H]-dione,”

Column 170, Table 3, Column “Example of Indication”, Row “maribavir”:

“Cancer, pancreatic”

Column 171, Table 3, Column “API Chemical Name”, Row “meluadrine”:

“(R\*,R\*)-2,3-dihydroxybutanedjoate (1:1) (salt) [CAS]”

Column 173, Table 3, Column “API Generic Name”:

“mepartncin”

Column 175, Table 3, Column “API Generic Name”:

“Methotnmeprazine”

Page 195, Table 3, Row “lobaplatin”:

<b>--Example of Therapeutic Use</b>	<b>Example of-- Indication</b>
Anticancer alkylating	Cancer, lung, small cell

Page 197, Table 3, Column “API Chemical Name”, Row “loratadine”:

--1-Piperidinecarboxylic acid--

Page 198, Table 3, Column “API Chemical Name”, Row “lurtotecan”:

--11H-1,4-Dioxino[2,3-g]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-9,12[8H,14H]-dione,--

Page 201, Table 3, Column “Example of Indication”, Row “maribavir”:

--Infection, cytomegalovirus--

Page 204, Table 3, Column “API Chemical Name”, Row “meluadrine”:

--(R\*,R\*)-2,3-dihydroxybutanedioate (1:1) (salt) [CAS]--

Page 205, Table 3, Column “API Generic Name”:

--mepartricin--

Page 208, Table 3, Column “API Generic Name”:

--Methotrimeprazine--

Column 175, Table 3, Row  
“Methylergonovine”:

Page 208, Table 3, Row “Methylergonovine”:

**“API Chemical                      CAS No.”**  
**Name**  
113-42-8

**--API Chemical                      CAS No.--**  
**Name**  
113-42-8

Column 177, Table 3, Column “API Generic  
Name”:

Page 209, Table 3, Column “API Generic  
Name”:

“Metnzamide”

--Metrizamide--

Column 179, Table 3, Column “API Chemical  
Name”, Row “misoprostol”:

Page 212, Table 3, Column “API Chemical  
Name”, Row “misoprostol”:

“Prost-13-en-1-oic acid, 11,16-dihydro 16-  
methyl-9-oxo,-”

--Prost-13-en-1-oic acid, 11,16-dihydroxy-16-  
methyl-9-oxo,-

Column 183, Table 3, Column “API Chemical  
Name”, Row “mycophenolate mofetil”:

Page 217, Table 3, Column “API Chemical  
Name”, Row “mycophenolate mofetil”:

“4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-  
methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-  
methyt,-”

--4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-  
6-methoxy-7-methyl-3-oxo-5-  
isobenzofuranyl)-4-methyl,-

Column 185, Table 3, Column “API Chemical  
Name”, Row “naltrexone”:

Page 219, Table 3, Column “API Chemical  
Name”, Row “naltrexone”:

“(SAlpha)-[CAS]”

--(5Alpha)-[CAS]--

Column 186, Table 3, Row “NAMI”:

Page 219, Table 3, Row “NAMI”:

**“Example of                      Example of”**  
**Therapeutic Use                      Indication**  
Anticancer, other

**--Example of                      Example of--**  
**Therapeutic Use                      Indication**  
Anticancer, other                      Cancer, general

Column 187, Table 3, Column “API Generic  
Name”:

Page 220, Table 3, Column “API Generic  
Name”:

“NGX-4016”

--NCX-4016--

<u>Column 187, Table 3, Column “API Chemical Name”, Row “nicaraven”:</u>	<u>Page 222, Table 3, Column “API Chemical Name”, Row “nicaraven”:</u>
“3-Pyndinecarboxamide, N,N-(1-methyl-1,2-ethanediyl)bis-[CAS]”	--3-Pyridinecarboxamide, N,N'-(1-methyl-1,2-ethanediyl)bis- [CAS]--
<u>Column 189, Table 3, Column “API Chemical Name”, Row “nicorandil”:</u>	<u>Page 222, Table 3, Column “API Chemical Name”, Row “nicorandil”:</u>
“3-Pyndinecarboxamide”	--3-Pyridinecarboxamide--
<u>Column 189, Table 3, Column “API Chemical Name”, Row “nicotine”:</u>	<u>Page 222, Table 3, Column “API Chemical Name”, Row “nicotine”:</u>
“Pyridine, 3-(1-methyl-2-pyrrolidinyl)-, (5)-[CAS]”	--Pyridine, 3-(1-methyl-2-pyrrolidinyl)-, (S)-[CAS]--
<u>Column 189, Table 3, Column “API Chemical Name”, Row “niperotidine”:</u>	<u>Page 224, Table 3, Column “API Chemical Name”, Row “niperotidine”:</u>
“[(dimethylamino)methyl]furfuryl]thio]ethyl]-2-nitro-N'-piperonyl-1,1-ethenediamine”	--N-[2-[[5-[(dimethylamino)methyl]furfuryl]thio]ethyl]-2-nitro-N'-piperonyl-1,1-ethenediamine--
<u>Column 191, Table 3, Column “API Chemical Name”, Row “NM-3”:</u>	<u>Page 225, Table 3, Column “API Chemical Name”, Row “NM-3”:</u>
“3-(2-methylcarboxymethyl)-6-methoxy-8-hydroxy-isocoumann”	--3-(2-methylcarboxymethyl)-6-methoxy-8-hydroxy-isocoumarin--
<u>Column 191, Table 3, Column “API Generic Name”:</u>	<u>Page 225, Table 3, Column “API Generic Name”:</u>
“N-Methylepinephne”	--N-Methylepinephrine--
<u>Column 192, Table 3, Column “Example of Indication”, Row “nitisinone”:</u>	<u>Page 224, Table 3, Column “Example of Indication”, Row “nitisinone”:</u>
“Cirrhosis”	--Cirrhosis, hepatic--



<u>Column 193, Table 3, Column “API Generic Name”:</u>	<u>Page 226, Table 3, Column “API Generic Name”:</u>
“Norelgestramin, Ethinyl Estradiol”	--Norelgestromin, Ethinyl Estradiol--
<u>Column 193, Table 3, Column “API Generic Name”:</u>	<u>Page 227, Table 3, Column “API Generic Name”:</u>
“Norgestnenone”	--Norgestrienone--
<u>Column 193, Table 3, Column “API Chemical Name”, Row “NV-07”:</u>	<u>Page 228, Table 3, Column “API Chemical Name”, Row “NV-07”:</u>
“2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-sec-pentyl-, 2-oxime [CAS]”	--2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-sec-pentyl-, 2-oxime [CAS]--
<u>Column 194, Table 3, Column “Example of Therapeutic Use”, Row “NS-220”:</u>	<u>Page 228, Table 3, Column “Example of Therapeutic Use”, Row “NS-220”:</u>
“Hypolipaeamic/Antitherosclerosis”	--Hypolipaeamic/Antiatherosclerosis--
<u>Column 195, Table 3, Column “API Generic Name”:</u>	<u>Page 229, Table 3, Column “API Generic Name”:</u>
“Octavenne”	--Octaverine--
<u>Column 195, Table 3, Column “API Chemical Name”, Row “octenidine”:</u>	<u>Page 229, Table 3, Column “API Chemical Name”, Row “octenidine”:</u>
“1-Octanamine, N,N-(1,10-decanediyl-di-1(4H)-pyridinyl-4-ylidene)bis-[CAS]”	--1-Octanamine, N,N'-(1,10-decanediyl-di-1(4H)-pyridinyl-4-ylidene)bis- [CAS]--
<u>Column 195, Table 3, Column “API Chemical Name”, Row “olmesartan medoxomil”:</u>	<u>Page 230, Table 3, Column “API Chemical Name”, Row “olmesartan medoxomil”:</u>
“1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-,”	--1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-,--

Column 195, Table 3, Column “API Chemical Name”, Row “omiloxetine”:

“Ethanone, 2-[(3R,4S)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-1-piperidinyl]-1-(4-fluorophenyl)-, rel-[CAS]”

Column 196, Table 3, Column “Example of Therapeutic Use”, Row “Omacor”:

“Hypolipaeic/Antithersclerosis”

Column 197, Table 3, Column “API Chemical Name”, Row “OPC-51803”:

“(5R)-2-[1-(2-chloro-4-(1-pyrolidinyl)benzoyl)-2,3,4,5-tetrahydro-1H-1-benzazepin-5-yl]-N-isopropylacetamide”

Column 197, Table 3, Column “API Chemical Name”, Row “Org-12962”:

“Piperazine, 1-[6-chloro-5-(trifluoromethyl)-2-pyridinyl]-, monohydrochionde [CAS]”

Column 197, Table 3, Column “API Chemical Name”, Row “ornoprostil”:

“Prost-13-en-1-oic acid, 11,15-dihydro-17,20-dimethyl-6,9-dioxo-, methyl ester, (11Alpha,13E,15S,17S)-[CAS]”

Column 198, Table 3, Row “OPC-31260”:

<b>“Example of Therapeutic Use Unspecified</b>	<b>Example of Indication</b>
--	----------------------------------

Page 231, Table 3, Column “API Chemical Name”, Row “omiloxetine”:

--Ethanone, 2-[(3R,4S)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-1-piperidinyl]-1-(4-fluorophenyl)-, rel- [CAS]--

Page 231, Table 3, Column “Example of Therapeutic Use”, Row “Omacor”:

--Hypolipaeic/Antiatherosclerosis--

Page 232, Table 3, Column “API Chemical Name”, Row “OPC-51803”:

--(5R)-2-[1-(2-chloro-4-(1-pyrolidinyl)benzoyl)-2,3,4,5-tetrahydro-1H-1-benzazepin-5-yl]-N-isopropylacetamide--

Page 232, Table 3, Column “API Chemical Name”, Row “Org-12962”:

--Piperazine, 1-[6-chloro-5-(trifluoromethyl)-2-pyridinyl]-, monohydrochloride [CAS]--

Page 233, Table 3, Column “API Chemical Name”, Row “ornoprostil”:

--Prost-13-en-1-oic acid, 11,15-dihydroxy-17,20-dimethyl-6,9-dioxo-, methyl ester, (11Alpha,13E,15S,17S)- [CAS]--

Page 232, Table 3, Row “OPC-31260”:

<b>--Example of Therapeutic Use Urological</b>	<b>Example of-- Indication Unspecified</b>
--	--

Column 200, Table 3, Column “Example of Therapeutic Use”, Row “oxandrolone”:

“Reproductive/gonad”

Page 234, Table 3, Column “Example of Therapeutic Use”, Row “oxandrolone”:

--Reproductive/gonadal, general--

Column 201, Table 3, Column “API Generic Name”:

“Oxypinocemphone”

Column 201, Table 3, Column “API Chemical Name”, Row “palindore”:

“2(5)-, (2E)-2-butendioate (1:1)”

Column 201, Table 3, Column “API Chemical Name”, Row “palonosetron”:

“3a5-2-[(S)-1-Azabicyclo[2.2.2]oct-3-yl]-2,3,3a,4,5,6-hexahydro-1-oxo-1H-benz[de]isoquinoline hydrochloride”

Column 202, Table 3, Row “PAI inhibs”:

**“Example of  
Therapeutic Use**  
Antithrombotic

**Example of”  
Indication**

Page 236, Table 3, Column “API Generic Name”:

--Oxypinocamphone--

Page 237, Table 3, Column “API Chemical Name”, Row “palindore”:

--2(S)-, (2E)-2-butendioate (1:1)--

Page 237, Table 3, Column “API Chemical Name”, Row “palonosetron”:

--3aS-2-[(S)-1-Azabicyclo[2.2.2]oct-3-yl]-2,3,3a,4,5,6-hexahydro-1-oxo-1H-benz[de]isoquinoline hydrochloride--

Page 237, Table 3, Row “PAI inhibs”:

**--Example of  
Therapeutic Use**  
Antithrombotic

**Example of--  
Indication**  
Thrombosis, venous

Column 205, Table 3, Column “API Chemical Name”, Row “pentamidine”:

“Benzenecarboximidamide, 4,4-[1,5-pentanediy]bis(oxy)]bis-[CAS]”

Column 205, Table 3, Column “API Chemical Name”, Row “peplomycin”:

“(5)-[CAS]”

Column 205, Table 3, Column “API Generic Name”:

“Pencyazine”

Page 241, Table 3, Column “API Chemical Name”, Row “pentamidine”:

--Benzenecarboximidamide, 4,4'-[1,5-pentanediy]bis(oxy)]bis- [CAS]--

Page 241, Table 3, Column “API Chemical Name”, Row “peplomycin”:

--(S)- [CAS]--

Page 242, Table 3, Column “API Generic Name”:

--Pericyazine--

<u>Column 206, Table 3, Column “Example of Therapeutic Use”, Row “pentostatin”:</u>	<u>Page 241, Table 3, Column “Example of Therapeutic Use”, Row “pentostatin”:</u>
“Anticancer, anticancer, antimetabolite”	--Anticancer, antimetabolite--
<u>Column 207, Table 3, Column “API Generic Name”:</u>	<u>Page 242, Table 3, Column “API Generic Name”:</u>
“Penmethazine”	--Perimethazine--
<u>Column 207, Table 3, Column “API Chemical Name”, Row “perisoxal”:</u>	<u>Page 242, Table 3, Column “API Chemical Name”, Row “perisoxal”:</u>
“1-Piperidineethanol, Alpha-(5-phenyl-3-isoxazolyl)-, 2-hydroxy-1,2,3-propanetricarboxylate (2:1) (salt) [CAS]”	--1-Piperidineethanol, Alpha-(5-phenyl-3-isoxazolyl)-, 2-hydroxy-1,2,3-propanetricarboxylate (2:1) (salt) [CAS]--
<u>Column 207, Table 3, Column “API Generic Name”:</u>	<u>Page 242, Table 3, Column “API Generic Name”:</u>
“Pertapine”	--Perlapine--
<u>Column 207, Table 3, Column “API Generic Name”:</u>	<u>Page 242, Table 3, Column “API Generic Name”:</u>
“Permethnn”	--Permethrin--
<u>Column 207, Table 3, Column “API Generic Name”:</u>	<u>Page 242, Table 3, Column “API Generic Name”:</u>
“PH-b”	--PH-10--
<u>Column 207, Table 3, Column “API Generic Name”:</u>	<u>Page 243, Table 3, Column “API Generic Name”:</u>
“Phenetunde”	--Pheneturide--
<u>Column 207, Table 3, Column “API Generic Name”:</u>	<u>Page 244, Table 3, Column “API Generic Name”:</u>
“Phenglutanmide”	--Phenglutarimide--

<u>Column 209, Table 3, Column “API Generic Name”:</u>	<u>Page 244, Table 3, Column “API Generic Name”:</u>
“Phenopendine”	--Phenoperidine--
<u>Column 209, Table 3, Column “API Generic Name”:</u>	<u>Page 245, Table 3, Column “API Generic Name”:</u>
“Pholednne”	--Pholedrine--
<u>Column 209, Table 3, Column “API Generic Name”:</u>	<u>Page 246, Table 3, Column “API Generic Name”:</u>
“pibaserod”	--piboserod--
<u>Column 209, Table 3, Column “API Generic Name”:</u>	<u>Page 246, Table 3, Column “API Generic Name”:</u>
“Picopenne”	--Picoperine--
<u>Column 211, Table 3, Column “API Chemical Name”, Row “pimilprost”:</u>	<u>Page 247, Table 3, Column “API Chemical Name”, Row “pimilprost”:</u>
“Acetic acid, [2-[octahydro-5-hydroxy-6-(3-hydroxy-5-methyl-1-nonenyl)-2-pentalenyl]ethoxy]-, methyl ester, [2R-[2Alpha,3Alpha,4Alpha (1E,3S,5S),5β,6aAlpha]]-[CAS]”	--Acetic acid, [2-[octahydro-5-hydroxy-6-(3-hydroxy-5-methyl-1-nonenyl)-2-pentalenyl]ethoxy]-, methyl ester, [2R-[2Alpha,3Alpha,4Alpha (1E,3S*,5S*),5β,6aAlpha]]- [CAS]--
<u>Column 211, Table 3, Column “API Chemical Name”, Row “pioglitazone”:</u>	<u>Page 247, Table 3, Column “API Chemical Name”, Row “pioglitazone”:</u>
“2,4-Thiazolidinedione, 5-[(4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl)methyl]-, monohydrochlond ( +/-)-[CAS]”	--2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl)methyl]-, monohydrochloride (+/-)- [CAS]--
<u>Column 213, Table 3, Column “API Generic Name”:</u>	<u>Page 248, Table 3, Column “API Generic Name”:</u>
“Pipenlate”	--Piperilate--

Column 213, Table 3, Column "API Generic Name":

"pipenne analogues"

Column 213, Table 3, Column "API Chemical Name", Row "pirmenol":

"(2-Pyridinemethanol, Alpha-[3-(2,6-dimethyl-1-piperidinyl)propyl]-.Alpha.phenyl-, cis-(+)- [CAS]"

Column 213, Table 3, Column "API Chemical Name", Row "piroxicam betadex":

"(β-Cyclodextrin"

Column 213, Table 3, Column "API Chemical Name", Row "piroxicam cinnamate":

"5,5-dioxide [CAS]"

Column 215, Table 3, Column "API Generic Name":

"pivampicillin/pivmecillinam"

Column 215, Table 3, Column "API Chemical Name", Row "pivmecillinam":

"[2S-(2Alpha,5Alpha,6β)]-[CAS]"

Column 217, Table 3, Column "API Generic Name":

"Potassium Permanganate"

Column 217, Table 3, Column "API Chemical Name", Row "pramipexole":

"(S)-[CAS]"

Page 248, Table 3, Column "API Generic Name":

--piperine analogues--

Page 250, Table 3, Column "API Chemical Name", Row "pirmenol":

--(2-Pyridinemethanol, Alpha-[3-(2,6-dimethyl-1-piperidinyl)propyl]-.Alpha.phenyl-, cis-(+)- [CAS]--

Page 250, Table 3, Column "API Chemical Name", Row "piroxicam betadex":

--β-Cyclodextrin--

Page 250, Table 3, Column "API Chemical Name", Row "piroxicam cinnamate":

--S,S-dioxide [CAS]--

Page 250, Table 3, Column "API Generic Name":

--pivampicillin/pivmecillinam--

Page 251, Table 3, Column "API Chemical Name", Row "pivmecillinam":

--[2S-(2Alpha,5Alpha,6β)]- [CAS]--

Page 253, Table 3, Column "API Generic Name":

--Potassium Permanganate--

Page 253, Table 3, Column "API Chemical Name", Row "pramipexole":

--(S)- [CAS]--

Column 218, Table 3, Row “prazosin”:

<b>“Example of Therapeutic Use</b>	<b>Example of Indication</b>
Antihypertensive,	

Column 219, Table 3, Column “API Chemical Name”, Row “pregabalin”:

“Hexanoic acid, 3-(aminomethyl)-5-methyl, (5)-[CAS]”

Column 219, Table 3, Column “API Chemical Name”, Row “Premarin + trimegestone”:

“Estra-4,9-dien-3-one, 17-(2-hydroxy-1-oxopropyl)-17-methyl-, [1711 (5)]-[CAS]”

Column 221, Table 3, Column “API Generic Name”:

“propionyl L-carnitine”

Column 221, Table 3, Row “propiverine”:

<b>“API Chemical Name</b>	<b>CAS No.”</b>
2,2-diphenyl-2-(1-propoxy) acetic acid (1-methylpiperid-4-yl) ester54556-98-8 hydrochloride	60569-19-9

Column 221, Table 3, Column “API Generic Name”:

“Propylhexedrine”

Column 221, Table 3, Column “API Chemical Name”, Row “proxigermanium”:

“Propanoic acid, 3,3'-(1,3-dioxo-1,3-digermoxanediyl)bis-[CAS]”

Page 254, Table 3, Row “prazosin”:

<b>--Example of Therapeutic Use</b>	<b>Example of-- Indication</b>
Antihypertensive, renin system	Hypertension, general

Page 255, Table 3, Column “API Chemical Name”, Row “pregabalin”:

--Hexanoic acid, 3-(aminomethyl)-5-methyl, (S)- [CAS]--

Page 255, Table 3, Column “API Chemical Name”, Row “Premarin + trimegestone”:

--Estra-4,9-dien-3-one, 17-(2-hydroxy-1-oxopropyl)-17-methyl-, [17B (S)]- [CAS]--

Page 257, Table 3, Column “API Generic Name”:

--propionyl L-carnitine--

Page 257, Table 3, Row “propiverine”:

<b>--API Chemical Name</b>	<b>CAS No.--</b>
2,2-diphenyl-2-(1-propoxy) acetic acid (1-methylpiperid-4-yl) ester hydrochloride	54556-98-8 60569-19-9

Page 258, Table 3, Column “API Generic Name”:

--Propylhexedrine--

Page 258, Table 3, Column “API Chemical Name”, Row “proxigermanium”:

--Propanoic acid, 3,3'-(1,3-dioxo-1,3-digermoxanediyl)bis- [CAS]--

Column 223, Table 3, Column “API Chemical Name”, Row “pseudoephedrine + triprolidine”:

“mixt. with (E)-2-[1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl]pyridine monohydrochloride [CAS]”

Column 223, Table 3, Column “CAS No.”, Row “pseudoephedrine”:

“90-82-4, 8054-271, 345-78-8”

Column 223, Table 3, Row “PX-12”:

<b>“API Generic Name</b>	<b>API Chemical Name”</b>
PX-12	1-Methylpropyl
disulfide	2-mercaptoimidazolyl

Column 223, Table 3, Column “API Generic Name”:

“Pyinthione”

Column 223, Table 3, Column “API Generic Name”:

“Pyronandine”

Column 223, Table 3, Column “API Generic Name”:

“Pyrrolnitnn”

Column 223, Table 3, Column “API Chemical Name”, Row “quetiapine”:

“Ethanol, 2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]-, (E)-2-butenedioate (2:1) (salt) [CAS]”

Page 259, Table 3, Column “API Chemical Name”, Row “pseudoephedrine + triprolidine”:

--mixt. with (E)-2-[1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl]pyridine monohydrochloride [CAS]--

Page 259, Table 3, Column “CAS No.”, Row “pseudoephedrine”:

--90-82-4, 8054-27-1, 345-78-8--

Page 259, Table 3, Row “PX-12”:

<b>--API Generic Name</b>	<b>API Chemical Name--</b>
PX-12	1-Methylpropyl 2-mercaptoimidazolyl disulfide

Page 259, Table 3, Column “API Generic Name”:

--Pyrithione--

Page 260, Table 3, Column “API Generic Name”:

--Pyronaridine--

Page 260, Table 3, Column “API Generic Name”:

--Pyrrolnitrin--

Page 260, Table 3, Column “API Chemical Name”, Row “quetiapine”:

--Ethanol, 2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]-, (E)-2-butenedioate (2:1) (salt) [CAS]--



<u>Column 223, Table 3, Column “API Generic Name”:</u>	<u>Page 260, Table 3, Column “API Generic Name”:</u>
“quinacnne”	--quinacrine--
<u>Column 224, Table 3, Column “Example of Indication”, Row “quinacrine”:</u>	<u>Page 260, Table 3, Column “Example of Indication”, Row “quinacrine”:</u>
“Creutzfeldt-Jakob disease”	--Creutzfeldt-Jakob disease--
<u>Column 225, Table 3, Column “API Chemical Name”, Row “quinaprilat”:</u>	<u>Page 261, Table 3, Column “API Chemical Name”, Row “quinaprilat”:</u>
“3-Isoquinolinecarboxylic acid, 2-[2-[(1-carboxy-3-phenylpropyl)amino]-1-oxopropyl]-1,2,3,4-tetrahydro-, [35-[2[R*(R*)],3R*]]-[CAS]”	--3-Isoquinolinecarboxylic acid, 2-[2-[(1-carboxy-3-phenylpropyl)amino]-1-oxopropyl]-1,2,3,4-tetrahydro-, [3S-[2[R*(R*)],3R*]]-[CAS]--
<u>Column 225, Table 3, Column “API Chemical Name”, Row “ramipril”:</u>	<u>Page 262, Table 3, Column “API Chemical Name”, Row “ramipril”:</u>
“Cyclopenta[b]pyrrole-2-carboxylic acid, 1-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydro-, [2S-[1[R*(R)],2Alpha,3aß,6aß]]-[CAS]”	--Cyclopenta[b]pyrrole-2-carboxylic acid, 1-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydro-, [2S-[1[R*(R*)],2Alpha,3aß,6aß]]-[CAS]--
<u>Column 225, Table 3, Column “API Chemical Name”, Row “ranitidine”:</u>	<u>Page 262, Table 3, Column “API Chemical Name”, Row “ranitidine”:</u>
“1,1-Ethenediamine, N-[2-([5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-N'-methyl-2-nitro-[CAS]”	--1,1-Ethenediamine, N-[2-([5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-N'-methyl-2-nitro-[CAS]--
<u>Column 225, Table 3, Column “API Chemical Name”, Row “ranolazine”:</u>	<u>Page 262, Table 3, Column “API Chemical Name”, Row “ranolazine”:</u>
“1-Piperazineacetamide, N-(2,6-dimethylphenyl)-4-(2-hydroxy-3-(2-methoxyphenoxy)propyl)-, (+/-)-[CAS]”	--1-Piperazineacetamide, N-(2,6-dimethylphenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]-, (+/-)- [CAS]--

Column 227, Table 3, Column “API Generic Name”:

“raxofeiat”

Column 227, Table 3, Column “API Chemical Name”, Row “repaglinide”:

“Benzoic acid, 2-ethoxy-4-[2-[[3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]amino]-2-oxoethyl]-, (5)-[CAS]”

Column 227, Table 3, Column “API Chemical Name”, Row “R-flurbiprofen”:

“[1,1-Biphenyl]-4-acetic acid, 2-fluoro-Alpha-methyl”

Column 227, Table 3, Column “API Generic Name”:

“Rho (D) Immune Globuhn (Human)”

Column 229, Table 3, Column “API Chemical Name”, Row “rifaximin”:

“[25-(2R\*,16Z,18E,20R\*,22S\*,23S\*,24S\*, 25R\*, 26S\*,27R\*,28E)]”

Column 231, Table 3, Column “API Chemical Name”, Row “ropivacaine”:

“2-Piperidinecarboxamide, N-(2,6-dimethylphenyl)-1-propyl-, (5)-[CAS]”

Column 231, Table 3, Column “API Chemical Name”, Row “rotigotine”:

“1-Naphthalenol, 5,6,7,8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-, (5)- [CAS]”

Page 263, Table 3, Column “API Generic Name”:

--raxofelast--

Page 264, Table 3, Column “API Chemical Name”, Row “repaglinide”:

--Benzoic acid, 2-ethoxy-4-[2-[[3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]amino]-2-oxoethyl]-, (S)- [CAS]--

Page 265, Table 3, Column “API Chemical Name”, Row “R-flurbiprofen”:

--[1,1'-Biphenyl]-4-acetic acid, 2-fluoro-Alpha-methyl--

Page 265, Table 3, Column “API Generic Name”

--Rho (D) Immune Globulin (Human)--

Page 266, Table 3, Column “API Chemical Name”, Row “rifaximin”:

--[2S-(2R\*,16Z,18E,20R\*,22S\*,23S\*,24S\*, 25R\*,26S\*,27R\*,28E)]--

Page 268, Table 3, Column “API Chemical Name”, Row “ropivacaine”:

--2-Piperidinecarboxamide, N-(2,6-dimethylphenyl)-1-propyl-, (S)- [CAS]--

Page 269, Table 3, Column “API Chemical Name”, Row “rotigotine”:

--1-Naphthalenol, 5,6,7,8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-, (S)- [CAS]--

Column 233, Table 3, Column “API Chemical Name”, Row “rubitecan”:

“1H-Pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione, 4-ethyl-4-hydroxy-10-nitro-, (5)-[CAS]”

Column 235, Table 3, Column “API Chemical Name”, Row “saquinavir”:

“Butanediamide, N1-[3-[3-[[[(1,1-dimethylethyl)amino]carbonyl]octahydro-2(1H)-isoquinolinyl]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, [3S-[CAS]”

Column 237, Table 3, Column “API Chemical Name”, Row “Sch-63390”:

“7H-Pyrazolo[4,3-e][1,2,4]tnazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-(3-phenylpropyl)-[CAS]”

Column 237, Table 3, Column “API Generic Name”:

“SGS technology”

Column 237, Table 3, Row “seratrodast”:

<b>“API Chemical Name</b>	<b>CAS No.”</b>
Benzeneheptanoic acid,	1103187-07-1
zeta-(2,4,5-trimethyl-3,6-	112665-43-7
dioxo-1,4-cyclohexadien-	
-yl)-, (+/-)-[CAS]	

Page 270, Table 3, Column “API Chemical Name”, Row “rubitecan”:

--1H-Pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione, 4-ethyl-4-hydroxy-10-nitro-, (S)- [CAS]--

Page 274, Table 3, Column “API Chemical Name”, Row “saquinavir”:

--Butanediamide, N1-[3-[3-[[[(1,1-dimethylethyl)amino]carbonyl]octahydro-2(1H)-isoquinolinyl]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, [3S-[2[1R\*(R\*),2S\*],3Alpha,4aß,8aß]]- [CAS]--

Page 275, Table 3, Column “API Chemical Name”, Row “Sch-63390”:

--7H-Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-(3-phenylpropyl)- [CAS]--

Page 275, Table 3, Column “API Generic Name”:

--SCS technology--

Page 276, Table 3, Row “seratrodast”:

<b>--API Chemical Name</b>	<b>CAS No.--</b>
Benzeneheptanoic acid,	103187-07-1
zeta-(2,4,5-trimethyl-3,6-	112665-43-7
dioxo-1,4-cyclohexadien-	
1-yl)-, (+/-)- [CAS]	

Column 237, Table 3, Column “API Chemical Name”, Row “sertindole”:

“2-Imidazolidinone, 1-[2-[4-[5-chloro-1-(4-fluorophenyl)-1H-indol-3-yl]-1-piperidinyl]ethyl]-[CAS]”

Column 240, Table 3, Column “Example of Therapeutic Use”, Row “silver sulfadiazine”:

“Anti-infective”

Column 239, Table 3, Column “API Chemical Name”, Row “sivelestat”:

“Glycine, N-[2-D[4-(2,2-dimethyl-1-oxopropoxy)phenyl]sulfonyl]amino]benzoyl]-[CAS]”

Column 241, Table 3, Column “API Chemical Name”, Row “SN-38”:

“(4S)-4,7,11-triethyl-3,4,12,14-tetrahydro-4,10-dihydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quindin-9-yl”

Column 241, Table 3, Column “API Chemical Name”, Row “soblidotin”:

“L-valinamide, N,N-dimethyl-L-valyl-N-[2-methoxy-4-L2-[1-methoxy-2-methyl-3-oxo-3-[(2-phenylethyl)amino]propyl]-1-pyrrolidinyl]-1-(2-methylpropyl)-4-oxobutyl]-N-methyl-, [2S-[1[1R\*(R\*),2S\*],2R\*(1S\*,2S\*)]]-[CAS]”

Column 241, Table 3, Column “API Chemical Name”, Row “sodium oxybate”:

“Butyric acid”

Page 276, Table 3, Column “API Chemical Name”, Row “sertindole”:

--2-Imidazolidinone, 1-[2-[4-[5-chloro-1-(4-fluorophenyl)-1H-indol-3-yl]-1-piperidinyl]ethyl]- [CAS]--

Page 277, Table 3, Column “Example of Therapeutic Use”, Row “silver sulfadiazine”:

--Anti-infective, other--

Page 278, Table 3, Column “API Chemical Name”, Row “sivelestat”:

--Glycine, N-[2-[[[4-(2,2-dimethyl-1-oxopropoxy)phenyl]sulfonyl]amino]benzoyl]-[CAS]--

Page 279, Table 3, Column “API Chemical Name”, Row “SN-38”:

--(4S)-4,7,11-triethyl-3,4,12,14-tetrahydro-4,10-dihydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quindin-9-yl--

Page 279, Table 3, Column “API Chemical Name”, Row “soblidotin”:

--L-valinamide, N,N-dimethyl-L-valyl-N-[2-methoxy-4-[2-[1-methoxy-2-methyl-3-oxo-3-[(2-phenylethyl)amino]propyl]-1-pyrrolidinyl]-1-(2-methylpropyl)-4-oxobutyl]-N-methyl-, [2S-[1[1R\*(R\*),2S\*],2R\*(1S\*,2S\*)]]- [CAS]--

Page 280, Table 3, Column “API Chemical Name”, Row “sodium oxybate”:

--Butyric acid--

Column 241, Table 3, Column “API Chemical Name”, Row “sodium prasterone sulfate”:

“3B-hydroxy-5-androsten-17-one(sodium sulfate dihydrate)”

Column 241, Table 3, Column “API Chemical Name”, Row “sofalcone”:

“Acetic acid, [5-((3-methyl-2-butenyl)oxy)-2-[3-[4-[(3-methyl-2-butenyl)oxy]phenyl]-1-oxo-2-propenyl]phenoxy]-[CAS]”

Column 243, Table 3, Column “API Chemical Name”, Row “SR-146131”:

“1H-Indole-1-acetic acid, 2-[[[4-(4-chloro-2,5-dimethoxyphenyl)-5-(2-cyclohexylethyl)-2-thiazolyl]amino]carbonyl]-5,7-dimethyl- [CAS]”

Column 243, Table 3, Column “API Chemical Name”, Row “β-alethine”:

“Propanamide, N, N(dithiodi-2,1-ethanediyl)bis(3-amino)-[CAS]”

Column 245, Table 3, Column “API Generic Name”:

“Stiibamidine”

Column 247, Table 3, Column “API Chemical Name”, Row “sufentanil”:

“Propanamide, N-[4-(methoxymethyl)-1-[2-(2-thienyl)ethyl]-4-piperidyl]-N-phenyl-[CAS]”

Page 280, Table 3, Column “API Chemical Name”, Row “sodium prasterone sulfate”:

--3β-hydroxy-5-androsten-17-one(sodium sulfate dihydrate)--

Page 280, Table 3, Column “API Chemical Name”, Row “sofalcone”:

--Acetic acid, [5-[(3-methyl-2-butenyl)oxy]-2-[3-[4-[(3-methyl-2-butenyl)oxy]phenyl]-1-oxo-2-propenyl]phenoxy]- [CAS]--

Page 282, Table 3, Column “API Chemical Name”, Row “SR-146131”:

--1H-Indole-1-acetic acid, 2-[[[4-(4-chloro-2,5-dimethoxyphenyl)-5-(2-cyclohexylethyl)-2-thiazolyl]amino]carbonyl]-5,7-dimethyl- [CAS]--

Page 283, Table 3, Column “API Chemical Name”, Row “β-alethine”:

--Propanamide, N, N'(dithiodi-2,1-ethanediyl)bis(3-amino)- [CAS]--

Page 284, Table 3, Column “API Generic Name”:

--Stilbamidine--

Page 285, Table 3, Column “API Chemical Name”, Row “sufentanil”:

--Propanamide, N-[4-(methoxymethyl)-1-[2-(2-thienyl)ethyl]-4-piperidyl]-N-phenyl- [CAS]--

Column 247, Table 3, Column “API Chemical Name”, Row “sulbenicillin”:

“4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-[(phenylsulfoacetyl)amino]-, [2S-[2Alpha,5Alpha,6a(S\*)]]-[CAS]”

Column 247, Table 3, Column “API Generic Name”:

“Sutfaguanole”

Column 247, Table 3, Column “API Generic Name”:

“Sutfapyndine”

Column 249, Table 3, Column “API Chemical Name”, Row “sultamicillin”:

“5, 5-dioxide,”

Column 249, Table 3, Column “API Chemical Name”, Row “sultopride”:

“Benzamide, N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-methoxy-[CAS]”

Column 251, Table 3, Column “API Chemical Name”, Row “T-1095”:

“1-Propanone, 3-(5-benzofuranyl)-1-(2-hydroxy-6-((6-O-methoxycarbonyl)-B-D-glucopyranosyl)oxy)-4-methylphenyl- [CAS]”

Page 285, Table 3, Column “API Chemical Name”, Row “sulbenicillin”:

--4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-[(phenylsulfoacetyl)amino]-, [2S-[2Alpha,5Alpha,6β(S\*)]]- [CAS]--

Page 286, Table 3, Column “API Generic Name”:

--Sulfaguanole--

Page 287, Table 3, Column “API Generic Name”:

--Sulfapyridine--

Page 288, Table 3, Column “API Chemical Name”, Row “sultamicillin”:

--S, S-dioxide,--

Page 288, Table 3, Column “API Chemical Name”, Row “sultopride”:

--Benzamide, N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)-2-methoxy-[CAS]--

Page 290, Table 3, Column “API Chemical Name”, Row “T-1095”:

--1-Propanone, 3-(5-benzofuranyl)-1-(2-hydroxy-6-((6-O-methoxycarbonyl)-β-D-glucopyranosyl)oxy)-4-methylphenyl- [CAS]--

Column 251, Table 3, Column “API Chemical Name”, Row “T-1249”:

“L-Phenylalaninamide, N-acetyl-L-tryptophyl-L-glutaminy-L-Alpha-glutamyl-L-tryptophyl-L-Alpha-glutamyl-L-glutaminy-L-lysyl-L-isoleucyl-L-threonyl-L-alanyl-L-leucyl-L-leucyl-L-Alpha-glutamyl-L-glutaminy-L-alanyl-L-glutaminy-L-isoleucyl-L-glutaminy-L-glutaminy-L-Alpha-glutamyl-L-lysyl-L-Alpha-glutamyl-asparaginy-L-tyrosyl-L-Alpha-glutamyl-L-leucyl-L-glutaminy-L-lysyl-L-leucyl-L-Alpha-aspartyl-L-lysyl-L-tryptophyl-L-ananyl-L-seryl-L-leucyl-L-tryptophyl-L-Alpha-glutamyl-L-tryptophyl [CAS]”

Column 251, Table 3, Column “API Chemical Name”, Row “TA-2005”:

“2(1H)-Quinolinone, 8-hydroxy-5-[1-hydroxy-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-, monohydrochloride, [R-(R\*,R\*)]-[CAS]”

Column 251, Table 3, Column “API Chemical Name”, Row “TA-993”:

“1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-8-methyl-2-(4-methylphenyl)-, (2R,3R)-rel(-)-, (2Z)-2-butenedioate [CAS]”

Column 251, Table 3, Column “API Chemical Name”, Row “tacalcitol”:

“9,10-Secachalesta-5,7,10(19)-triene-1,3,24-triol, (1Alpha,3β,5Z,7E,24R)- [CAS]”

Page 290, Table 3, Column “API Chemical Name”, Row “T-1249”:

--L-Phenylalaninamide, N-acetyl-L-tryptophyl-L-glutaminy-L-Alpha-glutamyl-L-tryptophyl-L-Alpha-glutamyl-L-glutaminy-L-lysyl-L-isoleucyl-L-threonyl-L-alanyl-L-leucyl-L-leucyl-L-Alpha-glutamyl-L-glutaminy-L-alanyl-L-glutaminy-L-isoleucyl-L-glutaminy-L-glutaminy-L-Alpha-glutamyl-L-lysyl-L-Alpha-glutamyl-asparaginy-L-tyrosyl-L-Alpha-glutamyl-L-leucyl-L-glutaminy-L-lysyl-L-leucyl-L-Alpha-aspartyl-L-lysyl-L-tryptophyl-L-ananyl-L-seryl-L-leucyl-L-tryptophyl-L-Alpha-glutamyl-L-tryptophyl- [CAS]--

Page 291, Table 3, Column “API Chemical Name”, Row “TA-2005”:

--2(1H)-Quinolinone, 8-hydroxy-5-[1-hydroxy-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-, monohydrochloride, [R-(R\*,R\*)]- [CAS]--

Page 291, Table 3, Column “API Chemical Name”, Row “TA-993”:

--1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-8-methyl-2-(4-methylphenyl)-, (2R,3R)-rel(-)-, (2Z)-2-butenedioate [CAS]--

Page 291, Table 3, Column “API Chemical Name”, Row “tacalcitol”:

--9,10-Secocholesta-5,7,10(19)-triene-1,3,24-triol, (1Alpha,3β,5Z,7E,24R)- [CAS]--

Column 251, Table 3, Column “API Chemical Name”, Row “tacedinaline”:

“Benzamide, 4-(acetamina)-N-(2-aminophenyl)-[CAS]”

Column 251, Table 3, Column “API Generic Name”:

“Tacralimus”

Column 251, Table 3, Column “API Chemical Name”, Row “tadalafil”:

“Pyrazina(1',2':1,6)pyrida(3,4-b)indole1,4-dione, 6-(1,3-benzadial-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-, (6R-trans) [CAS]”

Column 251, Table 3, Column “API Chemical Name”, Row “tafenoquine”:

“1,4-Pentanediamine, N4-[2,6-dimethoxy-4-methyl-5-[3-(trifluoramethyl)phenoxy]-8-quinoliny]- [CAS]”

Column 251, Table 3, Column “API Generic Name”:

“taflupaside”

Column 251, Table 3, Column “API Chemical Name”, Row “TAK-375”:

“(S)-N-[2-(1,6,7,8-Tetrahydro-2H-indeno-[5,4-bifuran-8-yl)]propionamide”

Column 253, Table 3, Column “API Chemical Name”, Row “taltirelin”:

“L-Prolinamide, N-[(hexahydro-1-methyl-2,6-dioxo-4-pyrimidinyl)carbonyl]-L-histidyl-, (S)-[CAS]”

Page 291, Table 3, Column “API Chemical Name”, Row “tacedinaline”:

--Benzamide, 4-(acetaminino)-N-(2-aminophenyl)- [CAS]--

Page 291, Table 3, Column “API Generic Name”:

--Tacrolimus--

Page 291, Table 3, Column “API Chemical Name”, Row “tadalafil”:

--Pyrazino(1',2':1,6)pyrido(3,4-b)indole1,4-dione, 6-(1,3-benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-, (6R-trans) [CAS]--

Page 291, Table 3, Column “API Chemical Name”, Row “tafenoquine”:

--1,4-Pentanediamine, N4-[2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]-8-quinoliny]- [CAS]--

Page 291, Table 3, Column “API Generic Name”:

--tafluposide--

Page 292, Table 3, Column “API Chemical Name”, Row “TAK-375”:

--(S)-N-[2-(1,6,7,8-Tetrahydro-2H-indeno-[5,4-b]furan-8-yl)]propionamide--

Page 293, Table 3, Column “API Chemical Name”, Row “taltirelin”:

--L-Prolinamide, N-[(hexahydro-1-methyl-2,6-dioxo-4-pyrimidinyl)carbonyl]-L-histidyl-, (S)- [CAS]--



Column 253, Table 3, Column “API Chemical Name”, Row “tamsulosin”:

“Benzenesulfonamide, 5-12-[[2-(2-ethoxyphenoxy)ethyl]amino]propyl]-2-methoxy-, (R)-[CAS]”

Column 253, Table 3, Column “API Chemical Name”, Row “tecastemizole”:

“1H-Benzimidazol-2-amine, 1-((4-fluorophenyl)methyl)-N-4-pipendinyl- [CAS]”

Column 254, Table 3, Column “Example of Therapeutic Use”, Row “talaporfin”:

“Radia/chemosensitizer”

Column 255, Table 3, Column “API Chemical Name”, Row “tedisamil”:

“Spiro[cyclopentane-1,9-[3,7]diazabicyclo[3.3.1]nonane], 3',7'-bis(cyclopropylmethyl)-[CAS]”

Column 255, Table 3, Column “API Chemical Name”, Row “telbivudine”:

“β-L-2-deoxythymidine”

Column 255, Table 3, Column “API Chemical Name”, Row “telmisartan”:

“(1,1-Biphenyl)-2-carboxylic acid”

Column 255, Table 3, Column “API Chemical Name”, Row “tenatoprazole”:

“1H-Imidazo(4,5-b)pyndine”

Page 293, Table 3, Column “API Chemical Name”, Row “tamsulosin”:

--Benzenesulfonamide, 5-[2-[[2-(2-ethoxyphenoxy)ethyl]amino]propyl]-2-methoxy-, (R)- [CAS]--

Page 294, Table 3, Column “API Chemical Name”, Row “tecastemizole”:

--1H-Benzimidazol-2-amine, 1-((4-fluorophenyl)methyl)-N-4-piperidinyl-[CAS]--

Page 292, Table 3, Column “Example of Therapeutic Use”, Row “talaporfin”:

--Radio/chemosensitizer--

Page 294, Table 3, Column “API Chemical Name”, Row “tedisamil”:

--Spiro[cyclopentane-1,9-[3,7]diazabicyclo[3.3.1]nonane], 3',7'-bis(cyclopropylmethyl)- [CAS]--

Page 295, Table 3, Column “API Chemical Name”, Row “telbivudine”:

--β-L-2'-deoxythymidine--

Page 295, Table 3, Column “API Chemical Name”, Row “telmisartan”:

--(1,1'-Biphenyl)-2-carboxylic acid--

Page 296, Table 3, Column “API Chemical Name”, Row “tenatoprazole”:

--1H-Imidazo(4,5-b)pyridine--

Column 255, Table 3, Column “API Chemical Name”, Row “teniposide”:

“Furo[3',4':6,7]naphthol[2,3-d]-1,3-dioxol-6(5aH)-one, 5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-9-[[4,6-O-(2-thienylmethylene)-β-D-glucopyranosyloxy]-, [5R-[5Alpha,5aβ,8aAlpha,9β(R\*)]]-[CAS]”

Column 257, Table 3, Column “API Chemical Name”, Row “terfenadine”:

“1-Pipendinebutanol, Alpha-[4-(1,1-dimethylethyl)phenyl]-4-(hydroxydiphenylmethyl)-[CAS]”

Column 257, Table 3, Column “API Chemical Name”, Row “terguride”:

“Urea, N,N-diethyl-N'-[(8Alpha)-6-methylergolin-8-yl]-[CAS]”

Column 259, Table 3, Column “API Generic Name”:

“thiacymse”

Column 259, Table 3, Column “CAS No.”, Row “Thimerfonate”:

“5964249”

Column 259, Table 3, Column “API Generic Name”:

“Tiadenol”

Column 259, Table 3, Column “API Chemical Name”, Row “tianeptine”:

“5,5-dioxide [CAS]”

Page 296, Table 3, Column “API Chemical Name”, Row “teniposide”:

--Furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one, 5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-9-[[4,6-O-(2-thienylmethylene)-β-D-glucopyranosyl]oxy]-, [5R-[5Alpha,5aβ,8aAlpha,9β(R\*)]]- [CAS]--

Page 297, Table 3, Column “API Chemical Name”, Row “terfenadine”:

--1-Piperidinebutanol, Alpha-[4-(1,1-dimethylethyl)phenyl]-4-(hydroxydiphenylmethyl)- [CAS]--

Page 297, Table 3, Column “API Chemical Name”, Row “terguride”:

--Urea, N,N-diethyl-N'-[(8Alpha)-6-methylergolin-8-yl]- [CAS]--

Page 299, Table 3, Column “API Generic Name”:

--thiacymserine--

Page 299, Table 3, Column “CAS No.”, Row “Thimerfonate”:

--5964-24-9--

Page 300, Table 3, Column “API Generic Name”:

--Tiadenol--

Page 300, Table 3, Column “API Chemical Name”, Row “tianeptine”:

--S,S-dioxide [CAS]--

Column 261, Table 3, Column “API Generic Name”:

“Tinondine”

Column 265, Table 3, Column “API Chemical Name”, Row “travoprost”:

“1-methylethylester (1R(1Alpha(Z),2B(1E,3R\*),3Alpha,5Alpha) [CAS]”

Column 265, Table 3, Column “API Chemical Name”, Row “trazodone”:

“1,2,4-Triazolo[4,3-a]pyridin-3(2H)-one, 2-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-[CAS]”

Column 269, Table 3, Column “API Chemical Name”, Row “trimipramine”:

“5H-Dibenz[b,f]azepine-5-propanamine, 10,11-dihydro-N,N,t1-trimethyl-, (Z)-2-butenedioate (1:1) [CAS]”

Column 269, Table 3, Column “API Chemical Name”, Row “trofosfamide”:

“3-2-(chloroethyl)-2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphonn 2-oxide”

Column 271, Table 3, Row “Valnoctamide”:

<b>“API Chemical Name</b>	<b>CAS No.”</b>
4171-13-5	

Column 271, Table 3, Column “API Generic Name”:

“Vaiproic Acid”

Page 302, Table 3, Column “API Generic Name”:

--Tinoridine--

Page 307, Table 3, Column “API Chemical Name”, Row “travoprost”:

--1-methylethylester (1R(1Alpha(Z),2B(1E,3R\*),3Alpha,5Alpha) [CAS]--

Page 307, Table 3, Column “API Chemical Name”, Row “trazodone”:

--1,2,4-Triazolo[4,3-a]pyridin-3(2H)-one, 2-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-[CAS]--

Page 309, Table 3, Column “API Chemical Name”, Row “trimipramine”:

--5H-Dibenz[b,f]azepine-5-propanamine, 10,11-dihydro-N,N,β-trimethyl-, (Z)-2-butenedioate (1:1) [CAS]--

Page 310, Table 3, Column “API Chemical Name”, Row “trofosfamide”:

--3-2-(chloroethyl)-2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorin 2-oxide--

Page 313, Table 3, Row “Valnoctamide”:

<b>--API Chemical Name</b>	<b>CAS No.--</b>
	4171-13-5

Page 313, Table 3, Column “API Generic Name”:

--Valproic Acid--

Column 272, Table 3, Row “tyloxapol”:**“Example of  
Therapeutic Use**Formulation, inhalable,  
topical**Example of  
Indication**Page 312, Table 3, Row “tyloxapol”:**--Example of  
Therapeutic Use**Formulation, inhalable,  
topical**Example of--  
Indication**

Cystic fibrosis

Column 273, Table 3, Column “API Chemical  
Name”, Row “vecuronium”:“Piperidinium, 1-bis(acetyloxy)-2-(1-  
piperidinylandrostan-16-yl)-1-methyl-  
[CAS]”Page 314, Table 3, Column “API Chemical  
Name”, Row “vecuronium”:--Piperidinium, 1-  
[(2 $\beta$ ,3 $\alpha$ ,5 $\alpha$ ,16 $\beta$ ,17 $\beta$ )-3,17-  
bis(acetyloxy)-2-(1-piperidinylandrostan-16-  
yl)-1-methyl-, [CAS]--Column 273, Table 3, Column “API Chemical  
Name”, Row “venlafaxine”:“Cyclohexanol, 1-[2-(dimethylamino)-1-(4-  
methoxyphenyl)ethyl]-, [CAS]”Page 314, Table 3, Column “API Chemical  
Name”, Row “venlafaxine”:--Cyclohexanol, 1-[2-(dimethylamino)-1-(4-  
methoxyphenyl)ethyl]-, [CAS]--Column 275, Table 3, Column “API Chemical  
Name”, Row “vinorelbine”:“C'-Norvincal leukoblastine, 3,4'-didehydro-4'-  
deoxy-[CAS]”Page 316, Table 3, Column “API Chemical  
Name”, Row “vinorelbine”:--C'-Norvincal leukoblastine, 3',4'-didehydro-  
4'-deoxy- [CAS]--Column 275, Table 3, Column “API Chemical  
Name”, Row “vinpocetine”:“Eburnamenine-14-carboxylic acid, ethyl ester,  
(3 $\alpha$ ,16 $\alpha$ )-[CAS]”Page 316, Table 3, Column “API Chemical  
Name”, Row “vinpocetine”:--Eburnamenine-14-carboxylic acid, ethyl  
ester, (3 $\alpha$ ,16 $\alpha$ )- [CAS]--Column 275, Table 3, Column “API Generic  
Name”:

“voriconazole”

Page 317, Table 3, Column “API Generic  
Name”:

--voriconazole--

Column 277, Table 3, Column “API Generic  
Name”:

“Yohimbine”

Page 319, Table 3, Column “API Generic  
Name”:


--Yohimbine--

Column 278, Table 3, Row "YT-146":**"Example of  
Therapeutic Use**  
Anti-inflammation,  
general**Example of"**  
**Indication**Page 319, Table 3, Row "YT-146":**--Example of  
Therapeutic Use**  
Anti-inflammatory**Example of--  
Indication**  
Inflammation, generalColumn 280, Table 3, Row "zinc acetate":**"Example of  
Therapeutic Use**  
Antiviral, other  
virus prophylaxis**Example of"**  
**Indication**Page 320, Table 3, Row "zinc acetate":**--Example of  
Therapeutic Use**  
Antiviral, other**Example of--  
Indication**  
Infection, herpes simplex  
virus prophylaxisColumn 279, Table 3, Column "API Chemical  
Name", Row "zolmitriptan":**"(5)-[CAS]"**Page 321, Table 3, Column "API Chemical  
Name", Row "zolmitriptan":**--(S)- [CAS]--.**

The fee of \$100.00 was paid at the time this Request was filed. The Commissioner is also authorized to charge any additional fees as required under 37 CFR 1.20(a) to Deposit Account No. 19-0065.

Approval of the Certificate of Correction is respectfully requested.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: P.O. Box 142950

Gainesville, FL 32614-2950

FCE/jb

Attachment: Certificate of Correction

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,790,905

Page 1 of 59

APPLICATION NO.: 10/747,742

DATED : September 7, 2010

INVENTORS : Mark Tawa, Orn Almarsson, Julius F. Remenar

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 3,

Line 60, "if their were" should read --if there were--.

Column 22,

Line 16, "((<sup>8</sup>1995-2002, Materials Data, Inc." should read  
--(<sup>8</sup>1995-2002, Materials Data, Inc.)--.

Line 63, "(D 2001" should read -© 2001--.

Column 24,

Line 24, "gly solvate" should read --glycol solvate--.

Column 27, Table 3,

Column "API Chemical Name", Row "(-)-amlodipine",  
"3-ethyl-S-methyl ester" should read --3-ethyl-5-methyl ester--.

Column 30, Table 3,

Column "Example of Indication", Row "5-azacitidine",  
"Myelodysplastic" should read --Myelodysplastic--.

Column 31, Table 3,

Column "CAS No.", Row "AC-5216",  
"2627-69-2" should read --blank--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk

P.O. Box 142950

Gainesville, FL 32614-2950

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,790,905

Page 2 of 59

APPLICATION NO.: 10/747,742

DATED : September 7, 2010

INVENTORS : Mark Tawa, Orn Almarsson, Julius F. Remenar

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 33, Table 3,

Column "API Chemical Name", Row "acrivastine + pseudoephedrine",

"[S-(R\*,R)]-" should read --[S-(R\*,R\*)]- --.

Column "API Chemical Name", Row "Adenoscan",

"6-Amino-9- $\beta$ -D-nbofuranosyl-9H-purine [CAS]" should read

--6-Amino-9- $\beta$ -D-ribofuranosyl-9H-purine [CAS]--.

Column 37, Table 3,

Column "API Chemical Name", Row "alizapride",

"1H-Benzotriazoie-5-carboxamide, 6-methoxy-N-[[1-(2-propenyl)-2-pyrrolidinyl)methyl]- [CAS]" should read

--1H-Benzotriazole-5-carboxamide, 6-methoxy-N-[[1-(2-propenyl)-2-pyrrolidinyl)methyl]- [CAS]--.

Column "API Chemical Name", Row "alprazolam",

"4H-[1,2,4]Triazolo[4,3-al][1,4]benzodiazepine" should read

--4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine--.

Column 38, Table 3,

Column "Example of Therapeutic Use", Row "alfuzosin",

"modivied-release" should read --modified-release--.

Column 39, Table 3,

Column "API Generic Name", "Amdinociiin Pivoxil" should read --Amdinocillin Pivoxil--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk

P.O. Box 142950

Gainesville, FL 32614-2950

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,790,905

Page 3 of 59

APPLICATION NO.: 10/747,742

DATED : September 7, 2010

INVENTORS : Mark Tawa, Orn Almarsson, Julius F. Remenar

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 40, Table 3,

Column "Example of Indication", Row "AMD-3100",  
"leocopenia" should read --leucopenia--.

Column 41, Table 3,

Row "Aminoguanidine",

"API Chemical Name CAS No." should read --API Chemical Name CAS No.--.  
79-17-4 79-17-4

Column 47, Table 3,

Column "API Chemical Name", Row "aprepitant",

"5-[[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro- [CAS]" should read  
--5-[[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro- [CAS]--.

Column 49, Table 3,

Column "API Chemical Name", Row "artemotil",

"12+62,12aR\*)]-[CAS]" should read --12 $\beta$ ,12aR\*)]- [CAS]--.

Column 50, Table 3,

Column "Example of Therapeutic Use", Row "atenolol",

"Antihypeertensive" should read --Antihypertensive--.

Column 52, Table 3,

Column "Example of Indication", Row "AZD-4282",

"Pain, neuronpathic" should read --Pain, neuropathic--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk

P.O. Box 142950

Gainesville, FL 32614-2950



UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,790,905

Page 4 of 59

APPLICATION NO.: 10/747,742

DATED : September 7, 2010

INVENTORS : Mark Tawa, Orn Almarsson, Julius F. Remenar

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 53, Table 3,

Column "API Generic Name", "aziocillin" should read --azlocillin--.

Column "API Chemical Name", Row "balofloxacin",

"3-Quinolonecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[3-(methylamino)-1-pipendinyl]-4-oxo-[CAS]" should read

--3-Quinolonecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[3-(methylamino)-1-piperidinyl]-4-oxo- [CAS]--.

Column "API Generic Name", "bamidipine" should read --barnidipine--.

Column "API Chemical Name", Row "betahistine",

"2-Pyndineethanamine" should read --2-Pyridineethanamine--.

Column 58, Table 3,

Column "Example of Therapeutic Use", Row "benzydamine",

"Stomatologic  
reproductive,  
inflammatory"

should read

--Stomatological  
reproductive/gonadal,  
anti-inflammatory--.

Column "Example of Therapeutic Use", Row "biapenem",

"Beta-lactam antibic" should read --Beta-lactam antibiotic--.

Column 59, Table 3,

Column "API Generic Name", "Betamiverine" should read --Bietamiverine--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk

P.O. Box 142950

Gainesville, FL 32614-2950

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,790,905

Page 5 of 59

APPLICATION NO.: 10/747,742

DATED : September 7, 2010

INVENTORS : Mark Tawa, Orn Almarsson, Julius F. Remenar

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 59, Table 3,

Column "API Chemical Name", Row "bimosiamose",

"(1,1-Biphenyl)-3-acetic acid, 3',3'''-(1,6-hexanediyl)bis(6-Alpha-D-mannopyranosyloxy)-, [CAS]" should read

--(1,1'-Biphenyl)-3-acetic acid, 3',3'''-(1,6-hexanediyl)bis(6'-Alpha-D-mannopyranosyloxy)-, [CAS]--.

Column 61, Table 3,

Column "API Chemical Name", Row "bosentan",

"Benzenesulfonamide, 4-(1,1-dimethylethyl)-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)[2,2-bipynmidin]-4-yl]-[CAS]" should read

--Benzenesulfonamide, 4-(1,1-dimethylethyl)-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)[2,2'-bipyrimidin]-4-yl]- [CAS]--.

Column 63, Table 3,

Column "API Chemical Name", Row "brivudin",

"Uridine, 5-(2-bromoethenyl)-2-deoxy, (E)-[CAS]" should read

--Uridine, 5-(2-bromoethenyl)-2'-deoxy, (E)- [CAS]--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk

P.O. Box 142950

Gainesville, FL 32614-2950

UNITED STATES PATENT AND TRADEMARK OFFICE  
CERTIFICATE OF CORRECTION

PATENT NO. : 7,790,905

Page 6 of 59

APPLICATION NO.: 10/747,742

DATED : September 7, 2010

INVENTORS : Mark Tawa, Orn Almarsson, Julius F. Remenar

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 66, Table 3,

Row "bunazosin",	<b>"Example of Therapeutic Use Antihypertens</b>	<b>Example of Indication"</b>
should read	<b>--Example of Therapeutic Use Antihypertensive, adrenergic</b>	<b>Example of Indication--.</b>  Hypertension, general

Column 67, Table 3,

Column "API Generic Name",  
"Calciuhi Mesoxalate" should read --Calcium Mesoxalate--.

Column 69, Table 3,

Column "API Chemical Name", Row "camptothecin",  
"4-Ethyl-4-hydroxy-1H-pyrano-[13'4':6,7]indolizinol[1,2-b;]quinoline-  
3,14(4H,12H)-dione microemulsion" should read  
--4-Ethyl-4-hydroxy-1H-pyrano-[13'4':6,7]indolizinol[1,2-b;]quinoline-  
3,14(4H,12H)-dione--.

Column 71, Table 3,

Column "API Chemical Name", Row "carmustine",  
"Urea, N,N-bis(2-chloroethyl)-N-nitroso- [CAS]" should read  
--Urea, N,N'-bis(2-chloroethyl)-N-nitroso- [CAS]--.

MAILING ADDRESS OF SENDER:  
Saliwanchik, Lloyd & Eisenschenk  
P.O. Box 142950  
Gainesville, FL 32614-2950

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,790,905

Page 7 of 59

APPLICATION NO.: 10/747,742

DATED : September 7, 2010

INVENTORS : Mark Tawa, Orn Almarsson, Julius F. Remenar

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 73, Table 3,

Column "API Chemical Name", Row "cefalexin",

"5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-  
[(aminophenylacetyl)amino]-3-methyl-oxo-, [CAS]" should read  
--5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-  
[(aminophenylacetyl)amino]-3-methyl-8-oxo-, [CAS]--.

Column "CAS No.", Row "cefalexin", "8105879-42-3" should read --105879-42-3--.

Column 75, Table 3,

Column "API Chemical Name", Row "cefmetazole",

"5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[(cyanomethyl)thio]  
acetyl]amino]-7-methoxy-3-[[[(1-methyl-1H-tetrazol-5-yl)thso]methyl]-8-oxo-,  
(6R-cis)-[CAS]" should read  
--5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[(cyanomethyl)thio]  
acetyl]amino]-7-methoxy-3-[[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-,  
(6R-cis)- [CAS]--.

Column "API Chemical Name", Row "cefonicid,

"[6R-[6Alpha,7B(R)]]-[CAS]" should read --[6R-[6Alpha,7β(R\*)]]-[CAS]--.

Column "API Chemical Name", Row "cefoperazone",

"[6R-[6Alpha,7β(R\*)]]-[CAS]" should read --[6R-[6Alpha,7β(R\*)]]-[CAS]--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk

P.O. Box 142950

Gainesville, FL 32614-2950

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,790,905

Page 8 of 59

APPLICATION NO.: 10/747,742

DATED : September 7, 2010

INVENTORS : Mark Tawa, Orn Almarsson, Julius F. Remenar

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 75, Table 3,

Column "API Chemical Name", Row "cefpimizole",

"[6R-[6Alpha,7β4R\*)]]-[CAS]" should read --[6R-[6Alpha,7β(R\*)]]- [CAS]--.

Column 77, Table 3,

Column "API Chemical Name", Row "cefpirome",

"[6R-[6Alpha,711(Z)]]-[CAS]" should read --[6R-[6Alpha,7β(Z)]]- [CAS]--.

Column "API Chemical Name", Row "cefuroxime axetil",

"5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,

3-[[[(aminocarbonyl)oxy]methyl]-7-[(2-furanyl(methoxyimino)acetyl]amino]-8-oxo-," should read

--5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,

3-[[[(aminocarbonyl)oxy]methyl]-7-[[2-furanyl(methoxyimino)acetyl]amino]-8-oxo--,--.

Column 78, Table 3,

Column "Patent Reference", Row "cefroxadine",

"143511" should read --1435111--.

Column "Patent Reference", Row "cefsulodin",

"138765" should read --1387656--.

Column "Patent Reference", Row "ceftazidime",

"202539" should read --2025398--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk

P.O. Box 142950

Gainesville, FL 32614-2950

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,790,905

Page 9 of 59

APPLICATION NO.: 10/747,742

DATED : September 7, 2010

INVENTORS : Mark Tawa, Orn Almarsson, Julius F. Remenar

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 81, Table 3,

Column "API Generic Name", "Chiorproethazine" should read --Chlorproethazine--.

Column "API Generic Name", "Chiorquinidol" should read --Chlorquinaldol--.

Column 83, Table 3,

Column "API Chemical Name", Row "choline-L-alfoscerate",

"Ethanaminium, 2-[[[(2,3-dihydroxypropoxy)hydroxyphosphinyl]xy]-N,N,N-trimethyl-," should read

--Ethanaminium, 2-[[[(2,3-dihydroxypropoxy)hydroxyphosphinyl]oxy]-N,N,N-trimethyl-,--.

Column 85, Table 3,

Column "API Generic Name", "cispiatin" should read --cisplatin--.

Column 89, Table 3,

Column "API Chemical Name", Row "CMI-392",

"Trans-2-[3-methoxy-4-(2-p-chlorophenylthio)ethoxy-5-(N-methyl-N'-hydroxyureidyl)methylphenyl]-5-(3,4,5-trimethoxyphenyl)tetrahydrofuran"

should read

--Trans-2-[3-methoxy-4-(2-p-chlorophenylthio)ethoxy-5-(N'-methyl-N'-hydroxyureidyl)methylphenyl]-5-(3,4,5-trimethoxyphenyl)tetrahydrofuran--.

Column "API Chemical Name", Row "CMT-3",

"(4a5,5aR,12a5)-[CAS]" should read --(4aS,5aR,12aS)- [CAS]--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk

P.O. Box 142950

Gainesville, FL 32614-2950

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,790,905

Page 10 of 59

APPLICATION NO.: 10/747,742

DATED : September 7, 2010

INVENTORS : Mark Tawa, Orn Almarsson, Julius F. Remenar

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 89, Table 3,

Column "API Chemical Name", Row "CNI-1493",

"Decanediarnide, N,N-bis[3,5-bis[1-[(aminoiminomethyl)hydrazono] ethyl]phenyl]-, tetrahydrochloride [CAS]" should read

--Decanediarnide, N,N'-bis [3,5-bis[1-[(aminoiminomethyl)hydrazono] ethyl]phenyl]-, tetrahydrochloride [CAS]--.

Column 90, Table 3,

Column "Example of Indication", Row "clopidogrel",

"myocardia" should read --myocardial--.

Column 91, Table 3,

Column "API Chemical Name", Row "CNS-5161",

"N-[2-chloro-5-(methylthio)phenyl]-N-methyl-N-[3-methylthio)phenyl]guanidine [CAS]" should read

--N'-[2-chloro-5-(methylthio)phenyl]-N-methyl-N-[3-methylthio)phenyl]guanidine [CAS]--.

Column 92, Table 3,

Row "CP-461",

**"Example of  
Therapeutic Use**  
Anticancer, other

**Example of Indication"**

should read --**Example of  
Therapeutic Use**  
Anticancer, other

**Example of Indication--.**

Cancer, prostate

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk

P.O. Box 142950

Gainesville, FL 32614-2950

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,790,905

Page 11 of 59

APPLICATION NO.: 10/747,742

DATED : September 7, 2010

INVENTORS : Mark Tawa, Orn Almarsson, Julius F. Remenar

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 92, Table 3,

Row “CRL-5861”,	“ <b>Example of Therapeutic Use</b> Antisickling	<b>Example of Indication”</b>
should read	-- <b>Example of Therapeutic Use</b> Antisickling	<b>Example of Indication--.</b>  Anaemia, sickle cell

Column 95, Table 3,

Column “API Chemical Name”, Row “cymserine”,

“(3aS,8aR)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-yl ester [CAS]” should read

--(3aS,8aR)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-yl ester [CAS]--.

Column “API Chemical Name”, Row “cyproterone”,

“(1 $\beta$ ,2 $\beta$ )-6-Chloro-1,2-dihydro-17-hydroxy-3H-cyclopropa[1,2]pregna-1,4,6-triene-3,20-dione [CAS]” should read

--(1 $\beta$ ,2 $\beta$ )-6-Chloro-1,2-dihydro-17-hydroxy-3'H-cyclopropa[1,2]pregna-1,4,6-triene-3,20-dione [CAS]--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk

P.O. Box 142950

Gainesville, FL 32614-2950



UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,790,905

Page 12 of 59

APPLICATION NO.: 10/747,742

DATED : September 7, 2010

INVENTORS : Mark Tawa, Orn Almarsson, Julius F. Remenar

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 95, Table 3,

Column "API Chemical Name", Row "dalfopristin + quinupristin",  
"mixt with 4-(4-(dimethylamino)-N-methyl-L-phenylalanine)-5-(5-((1-azabicyclo(2.2.2)oct-3-ylthio)methyl)-4-oxo-L-2-pipendinecarboxylic acid) virginiamycin S1- [CAS]" should read  
--mixt with 4-(4-(dimethylamino)-N-methyl-L-phenylalanine)-5-(5-((1-azabicyclo(2.2.2)oct-3-ylthio)methyl)-4-oxo-L-2-piperidinecarboxylic acid) virginiamycin S1- [CAS]--.

Column 97, Table 3,

Row "DB-67",

<b>"API Generic Name</b>	<b>API Chemical Name"</b>
DB-67 hydroxy- camptothecin	7-tert-Butyldimethylsiyl-10-

should read

<b>--API Generic Name</b>	<b>API Chemical Name--.</b>
DB-67	7-tert-Butyldimethylsiyl-10-hydroxycamptothecin

Column 99, Table 3,

Column "API Generic Name", "Delmadinane" should read --Delmadinone--.

MAILING ADDRESS OF SENDER:  
Saliwanchik, Lloyd & Eisenschenk  
P.O. Box 142950  
Gainesville, FL 32614-2950

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,790,905

Page 13 of 59

APPLICATION NO.: 10/747,742

DATED : September 7, 2010

INVENTORS : Mark Tawa, Orn Almarsson, Julius F. Remenar

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 100, Table 3,

Row “dersalazine”,

**“Example of  
Therapeutic Use**  
Anti-inflammatory

**Example of Indication”**

should read

**--Example of  
Therapeutic Use**  
Anti-inflammatory

**Example of Indication--.**

Colitis, ulcerative

Column 101, Table 3,

Column “API Chemical Name”, Row “dexrazoxane”,

“2,6-Piperazinedione, 4,4'-(1-methyl-1,2-ethanediyl)bis-, (5)- [CAS]” should read  
--2,6-Piperazinedione, 4,4'-(1-methyl-1,2-ethanediyl)bis-, (S)- [CAS]--.

Column “API Chemical Name”, Row “dextropropoxyphene”,

“[S-(R,S\*)]-[CAS]” should read --[S-(R\*,S\*)]- [CAS]--.

Column “API Chemical Name”, Row “dibekacin”,

“D-Streptamine, O-3-amino-3-deoxy-Alpha-D-glucopyranosyl-(1-6)-O-[2,6-diamino-2,3,4,6-tetradeoxy-Alpha-D-erythro-hexopyranosyl-(1-4)]-2-deoxy-, sulfate (salt)[CAS]” should read

--D-Streptamine, O-3-amino-3-deoxy-Alpha-D-glucopyranosyl-(1-6)-O-[2,6-diamino-2,3,4,6-tetradeoxy-Alpha-D-erythro-hexopyranosyl-(1-4)]-2-deoxy-, sulfate (salt)[CAS]--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk

P.O. Box 142950

Gainesville, FL 32614-2950

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,790,905

Page 14 of 59

APPLICATION NO.: 10/747,742

DATED : September 7, 2010

INVENTORS : Mark Tawa, Orn Almarsson, Julius F. Remenar

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 105, Table 3,

Column "API Generic Name", "Diisapropylamine" should read --Diisopropylamine--.

Column "API Chemical Name", Row "dinoprostone",

"Prosta-5,13-dien-1-oic acid, 11,15-dihydroxy-9-oxo-, (5Z, 11 Alpha, 13E, 15S)-[CAS]" should read

--Prosta-5,13-dien-1-oic acid, 11,15-dihydroxy-9-oxo-, (5Z,11 Alpha,13E,15S)-[CAS]--.

Column "API Generic Name", "Dioxethednne" should read --Dioxethedrine--.

Column 107, Table 3,

Column "API Generic Name", "Dastigmine" should read --Distigmine--.

Column "API Chemical Name", Row "DK-507k",

"(-)-7-[(7S)-7-Amino-5-azaspiro[2,4]heptan-5-yl]-6-fluoro-1-[(1R,2S)-2-fluoro-1-cyclopropyl]-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid hydrochloride monohydrate" should read

--(-)-7-[(7S)-7-Amino-5-azaspiro[2,4]heptan-5-yl]-6-fluoro-1-[(1R,2S)-2-fluoro-1-cyclopropyl]-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid hydrochloride monohydrate--.

Column "API Chemical Name", Row "dofetilide",

"Methanesulfonamide, N-[4-[2-[methyl[2-[4[(methylsulfonyl) amino]phenoxy]ethyl]amino]ethyl]phenyl]-[CAS]" should read

--Methanesulfonamide, N-[4-[2-[methyl[2-[4[(methylsulfonyl) amino]phenoxy]ethyl]amino]ethyl]phenyl]- [CAS]--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk

P.O. Box 142950

Gainesville, FL 32614-2950

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,790,905

Page 15 of 59

APPLICATION NO.: 10/747,742

DATED : September 7, 2010

INVENTORS : Mark Tawa, Orn Almarsson, Julius F. Remenar

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 108, Table 3,

Column "Example of Therapeutic Use", Row "docusate",

"Formulation, derm" should read --Formulation, dermal, topical--.

Column 109, Table 3,

Column "API Generic Name", "Domiodoi" should read --Domiodol--.

Column "API Generic Name", "darzolamide" should read --dorzolamide--.

Column "API Chemical Name", Row "dorzolamide + timolol",

"4H-Thieno(2,3-b)thiopyran-2-sulfonamide, 4-(ethylamino)-5,6-dihydro-6-methyl-7,7-dioxide (4S-trans) + ethyl 2-propanol, 1-[(1,1-dimethylamino)-3-[[4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl]oxy]-, (5), (Z)-2-butenedioate (1:1) (salt) [CAS]" should read

--4H-Thieno(2,3-b)thiopyran-2-sulfonamide, 4-(ethylamino)-5,6-dihydro-6-methyl-7,7-dioxide (4S-trans) + ethyl 2-propanol, 1-[(1,1-dimethylamino)-3-[[4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl]oxy]-, (S), (Z)-2-butenedioate (1:1) (salt) [CAS]--.

Column 113, Table 3,

Column "API Chemical Name", Row "E-1010",

"1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 6-[(1R)-1-hydroxyethyl]-3-[[[(3S,5S)-5-[(R)-hydroxy(3R)-3-pyrrolidinylmethyl]-3-pyrrolidinyl]thio]-4-methyl-7-oxo-, monohydrochionde, (4R,5S,6S)-[CAS]" should read

--1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 6-[(1R)-1-hydroxyethyl]-3-[[[(3S,5S)-5-[(R)-hydroxy(3R)-3-pyrrolidinylmethyl]-3-pyrrolidinyl]thio]-4-methyl-7-oxo-, monohydrochloride, (4R,5S,6S)- [CAS]--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk

P.O. Box 142950

Gainesville, FL 32614-2950

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,790,905

Page 16 of 59

APPLICATION NO.: 10/747,742

DATED : September 7, 2010

INVENTORS : Mark Tawa, Orn Almarsson, Julius F. Remenar

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 113, Table 3,

Column "API Chemical Name", Row "E-2101",

"N-Ethyl-(1-[1-(2-fluorophenethyl)pipendin-4-yl]-1H-indol-6-yl)acetamide"  
should read

--N-Ethyl-(1-[1-(2-fluorophenethyl)piperidin-4-yl]-1H-indol-6-yl)acetamide--.

Column "API Chemical Name", Row "E-5842",

"Pyridine, 4-(4-fluorophenyl)-1,2,3,6-tetrahydro-1-[4-(1H-1,2,4-triazol-1-yl)butyl]-, 2-hydroxy-1,2,3-propanetncarboxylate (1:1) [CAS]" should read  
--Pyridine, 4-(4-fluorophenyl)-1,2,3,6-tetrahydro-1-[4-(1H-1,2,4-triazol-1-yl)butyl]-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) [CAS]--.

Column 115, Table 3,

Column "API Generic Name",

"Edetate Galcium Disodium" should read --Edetate Calcium Disodium--.

Column 116, Table 3,

Column "Example of Therapeutic Use", Row "eflucimibe",

"Hypolipaemic/Antitherosclerosis" should read  
--Hypolipaemic/Antiatherosclerosis--.

Column 118, Table 3,

Column "Example of Therapeutic Use", Row "enoxacin",

"Quinolone antibacter" should read  
--Quinolone antibacterial--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk

P.O. Box 142950

Gainesville, FL 32614-2950

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,790,905

Page 17 of 59

APPLICATION NO.: 10/747,742

DATED : September 7, 2010

INVENTORS : Mark Tawa, Orn Almarsson, Julius F. Remenar

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 119, Table 3,

Column "API Chemical Name", Row "eperisone",

"1-Propanone, 1-(4-ethylphenyl)-2-methyl-3-(1-pipendinyl)- [CAS]" should read  
--1-Propanone, 1-(4-ethylphenyl)-2-methyl-3-(1-piperidinyl)- [CAS]--.

Column "API Generic Name", "Epiclilin" should read --Epicillin--.

Column "API Generic Name", "Epinzole" should read --Epirizole--.

Row "Epitiostanol",

<b>"API Chemical Name</b>	<b>CAS No."</b>
2363-58-8	

should read

<b>--API Chemical Name</b>	<b>CAS No.--.</b>
2363-58-8	

Column "API Chemical Name", Row "eptaplatin",

"Platinum, [(4R,5R)-2-(1-methylethyl)-1,3-dioxolane-4,5-dimethanamine-  
kappaN4',kappaN5][propanedioato(2-)-kappaO1,kappaO3]-, (SP-4-2)-[CAS]"

should read

--Platinum, [(4R,5R)-2-(1-methylethyl)-1,3-dioxolane-4,5-dimethanamine-  
kappaN4,kappaN5][propanedioato(2-)-kappaO1,kappaO3]-, (SP-4-2)- [CAS]--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk

P.O. Box 142950

Gainesville, FL 32614-2950

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,790,905

Page 18 of 59

APPLICATION NO.: 10/747,742

DATED : September 7, 2010

INVENTORS : Mark Tawa, Orn Almarsson, Julius F. Remenar

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 119, Table 3,

Row "Eptastigmine",

<b>"API Chemical Name</b>	<b>CAS No."</b>
-------------------------------	-----------------

101246-68-8

should read

<b>--API Chemical Name</b>	<b>CAS No.--</b>
	101246-68-8

Column 121, Table 3,

Column "API Chemical Name", Row "escitalopram",

"(5)- [CAS]" should read --(S)- [CAS]--.

Column "API Generic Name", "Etafedrine" should read --Etafedrine--.

Column 123, Table 3,

Column "API Generic Name", "Etilefnn" should read --Etilefrin--.

Column 125, Table 3,

Column "API Chemical Name", Row "exatecan",

"10H,13H-Benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-10,13-diane, 1-amino-9-ethyl-5-fluoro-1,2,3,9,12,15-hexahydro-9-hydroxy-4-methyl-, (1S,9S)-, [CAS]" should read

--10H,13H-Benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-10,13-dione, 1-amino-9-ethyl-5-fluoro-1,2,3,9,12,15-hexahydro-9-hydroxy-4-methyl-, (1S,9S)-, [CAS]--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk

P.O. Box 142950

Gainesville, FL 32614-2950

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,790,905

Page 19 of 59

APPLICATION NO.: 10/747,742

DATED : September 7, 2010

INVENTORS : Mark Tawa, Orn Almarsson, Julius F. Remenar

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 125, Table 3,

Column "API Chemical Name", Row "exemestane",

"Androsta-1,4-diene-3,17-diane, 6-methylene-[CAS]" should read

--Androsta-1,4-diene-3,17-dione, 6-methylene- [CAS]--.

Column "API Chemical Name", Row "ezetimibe",

"2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)-[CAS]" should read

--2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)- [CAS]--.

Column 129, Table 3,

Column "API Generic Name", "Ferrous Gluconate" should read --Ferrous Gluconate--.

Column "API Chemical Name", Row "ferumoxytol",

"Polyglucose sorbitol carboxymethyl ether-coated non-stoichiometric magnetite Imaging agent"

should read

--Polyglucose sorbitol carboxymethyl ether-coated non-stoichiometric magnetite--.

Column "API Chemical Name", Row "fexofenadine",

"Benzeneacetic acid, 4-[1-hydroxy-4-[4(hydroxydiphenylmethyl)-1-pipendinyl]butyl]-Alpha,Alpha-dimethyl-, [CAS]" should read

--Benzeneacetic acid, 4-[1-hydroxy-4-[4(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-Alpha,Alpha-dimethyl-, [CAS]--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk

P.O. Box 142950

Gainesville, FL 32614-2950



UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,790,905

Page 20 of 59

APPLICATION NO.: 10/747,742

DATED : September 7, 2010

INVENTORS : Mark Tawa, Orn Almarsson, Julius F. Remenar

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 129, Table 3,

Column "API Chemical Name", Row "fidarestat",

"Spiro(4H-1-benzopyran-4,4-imidazolidine)-2-carboxamide, 6-fluoro-2,3-dihydro-2',5'-dioxo-, (2S-cis)-, [CAS]" should read

--Spiro(4H-1-benzopyran-4,4'-imidazolidine)-2-carboxamide, 6-fluoro-2,3-dihydro-2',5'-dioxo-, (2S-cis)-, [CAS]--.

Column 131, Table 3,

Column "API Generic Name",

"Fludeoxyglucose F1B" should read --Fludeoxyglucose F18--.

Column "API Chemical Name", Row "flurbiprofen",

"[1,1-Biphenyl]-4-acetic acid, 2-fluoro-Alpha-methyl-[CAS]" should read

--[1,1'-Biphenyl]-4-acetic acid, 2-fluoro-Alpha-methyl- [CAS]--.

Column 133, Table 3,

Column "API Chemical Name", Row "flutazolam",

"Oxazolo[3,2-d][1,4]benzodiazepin-6(SH)-one, 10-chloro-11b-(2-fluorophenyl)-2,3,7,11b-tetrahydro-7-(2-hydroxyethyl)-[CAS]" should read

--Oxazolo[3,2-d][1,4]benzodiazepin-6(5H)-one, 10-chloro-11b-(2-fluorophenyl)-2,3,7,11b-tetrahydro-7-(2-hydroxyethyl)- [CAS]--.

Column 135, Table 3,

Column "API Chemical Name", Row "fumagiline",

"[3R-(3Alpha,4Alpha(2R\*,3R\*),5β,6β(all-E))]- [CAS]" should read

--[3R-[3Alpha,4Alpha(2R\*,3R\*),5β,6β(all-E))]- [CAS]--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk

P.O. Box 142950

Gainesville, FL 32614-2950

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,790,905

Page 21 of 59

APPLICATION NO.: 10/747,742

DATED : September 7, 2010

INVENTORS : Mark Tawa, Orn Almarsson, Julius F. Remenar

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 137, Table 3,

Column "API Generic Name", "Gepef rifle" should read --Gepefrine--.

Column 138, Table 3,

Column "Example of Therapeutic Use", Row "gallium nitrate",  
"Osteoporosh" should read --Osteoporosis treatment--.

Column 139, Table 3,

Column "API Chemical Name", Row "gimatecan",  
"dimethylethoxy)imino)methyl]-4-ethyl-4-hydroxy-1-12-dihydro-14H-pyrano[3,4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione" should read  
--(4S)-11-[(E)-[(1,1-dimethylethoxy)imino] methyl]-4-ethyl-4-hydroxy-1-12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione--.  
Column "API Generic Name", "Giyburide" should read --Glyburide--.

Column 141, Table 3,

Column "API Generic Name", "griseofuivin" should read --griseofulvin--.  
Column "API Chemical Name", Row "GYKI-16084",  
"(+)-R-2-{3-[N-(2-Benzo[1,4]dioxanylmethyl)amino]-1-propyl}-3(2H)-pyndazinone hydrochloride" should read  
--(+)-R-2-{3-[N-(2-Benzo[1,4]dioxanylmethyl)amino]-1-propyl}-3(2H)-pyridazinone hydrochloride--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk  
P.O. Box 142950  
Gainesville, FL 32614-2950

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,790,905

Page 22 of 59

APPLICATION NO.: 10/747,742

DATED : September 7, 2010

INVENTORS : Mark Tawa, Orn Almarsson, Julius F. Remenar

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 143, Table 3,

Column "API Generic Name", "HGP-6" should read --HGP-6<sup>^</sup>--.

Column 145, Table 3,

Column "API Generic Name",

"Hydroxychloroquine" should read --Hydroxychloroquine--.

Column "API Chemical Name", Row "hyoscyamine",

"benzeneacetic acid, Alpha(hydroxymethyl)-, 8-methyl-B-azabicyclo [3.2.1.]oct-3-yl ester, [3(S)-endo]," should read

--benzeneacetic acid, Alpha(hydroxymethyl)-, 8-methyl-8-azabicyclo [3.2.1.]oct-3-yl ester, [3(S)-endo],--.

Column "API Chemical Name", Row "ibopamine",

"Propanoic acid, 2-methyl-, 4-12-(methylamino)ethyl]-1,2-phenylene ester-[CAS]" should read

--Propanoic acid, 2-methyl-, 4-[2-(methylamino)ethyl]-1,2-phenylene ester-[CAS]--.

Column 147, Table 3,

Column "API Chemical Name", Row "indeloxazine",

"Morptioline" should read --Morpholine--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk

P.O. Box 142950

Gainesville, FL 32614-2950

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,790,905

Page 23 of 59

APPLICATION NO.: 10/747,742

DATED : September 7, 2010

INVENTORS : Mark Tawa, Orn Almarsson, Julius F. Remenar

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 149, Table 3,

Column "API Chemical Name", Row "indinavir",

"D-erythro-Pentonamide, 2,3,5-trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl), [1S-[1Alpha(R\*),2Alpha]]-, [CAS]" should read

--D-erythro-Pentonamide, 2,3,5-trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl), [1S-[1Alpha(R\*),2Alpha]]-, [CAS]--.

Column "API Chemical Name", Row "indisulam",

"1,4-Benzenedisulfonamide, N-(3-chloro-1H-indol-7-yl)-[CAS]" should read

--1,4-Benzenedisulfonamide, N-(3-chloro-1H-indol-7-yl)- [CAS]--.

Column 151, Table 3,

Column "API Chemical Name", Row "irofulven",

"Spiro[cyclopropane-1,5-[5H]inden]-7'(6'H)-one, 6'-hydroxy-2',4',6'-trimethyl-, (R)-[CAS]" should read

--Spiro[cyclopropane-1,5'-[5H]inden]-7'(6'H)-one, 6'-hydroxy-2',4',6'-trimethyl-, (R)- [CAS]--.

Column "API Chemical Name", Row "isepamicin",

"D-Streptamine, O-6-amino-6-deoxy-Alpha-D-glucopyranosyl-(1-4)-O-[3-deoxy-4-C-methyl-3-(methylamino)-β-L-arabinopyranosyl-(1-6)]-N1-(3-amino-2-hydroxy-1-oxopropyl)-2-deoxy-, (S)- [CAS]" should read

--D-Streptamine, O-6-amino-6-deoxy-Alpha-D-glucopyranosyl-(1-4)-O-[3-deoxy-4-C-methyl-3-(methylamino)-β-L-arabinopyranosyl-(1-6)]-N1-(3-amino-2-hydroxy-1-oxopropyl)-2-deoxy-, (S)- [CAS]--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk

P.O. Box 142950

Gainesville, FL 32614-2950

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,790,905

Page 24 of 59

APPLICATION NO.: 10/747,742

DATED : September 7, 2010

INVENTORS : Mark Tawa, Orn Almarsson, Julius F. Remenar

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 152, Table 3,

Column "Example of Indication", Row "isepamicin",

"Infection, fungal, general" should read --Infection, dermatological--.

Column 153, Table 3,

Column "API Chemical Name", Row "israpafant",

"6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine, 4-(2-chlorophenyl)-6,9-dimethyl-2-[2-[4-(2-methylpropyl)phenyl]ethyl]-[CAS]" should read

--6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine, 4-(2-chlorophenyl)-6,9-dimethyl-2-[2-[4-(2-methylpropyl)phenyl]ethyl]-[CAS]--.

Column 155, Table 3,

Column "API Chemical Name", Row "JTV-519",

"1,4-Benzothiazepine, 2,3,4,5-tetrahydro-7-methoxy-4-[1-oxo-3-[4-(phenylmethyl)-1-piperidinylopropyl]- [CAS]" should read

--1,4-Benzothiazepine, 2,3,4,5-tetrahydro-7-methoxy-4-[1-oxo-3-[4-(phenylmethyl)-1-piperidinylopropyl]- [CAS]--.

Column "API Chemical Name", Row "KCB-328",

"Methanesulfonamide, N-[3-amino-4-[2-[[2-(3,4-dimethoxyphenyl)ethyl] methylamino]ethoxy]phenyl]-, monohydrochloride [CAS]" should read

--Methanesulfonamide, N-[3-amino-4-[2-[[2-(3,4-dimethoxyphenyl)ethyl] methylamino]ethoxy]phenyl]-, monohydrochloride [CAS]--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk

P.O. Box 142950

Gainesville, FL 32614-2950

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,790,905

Page 25 of 59

APPLICATION NO.: 10/747,742

DATED : September 7, 2010

INVENTORS : Mark Tawa, Orn Almarsson, Julius F. Remenar

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 157, Table 3,

Column "API Generic Name", "KUL7211" should read --KUL-7211--.

Column "API Chemical Name", Row "L-758298",

"Phosphonic acid, [3-fl(2R,3S)-2-.(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl)methyl]-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]-[CAS]" should read

--Phosphonic acid, [3-[[[(2R,3S)-2-.(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl)methyl]-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]-[CAS]--.

Column "API Chemical Name", Row "landiolol",

"Benzenepropanoic acid, 4-[2-hydroxy-3-morpholinylcarbonyl)amino]ethyl]amino]propoxy]-, should read

--Benzenepropanoic acid, 4-[2-hydroxy-3-[[2-[(4-Morpholinylcarbonyl)amino]ethyl]amino]propoxy]-,--.

Column "API Chemical Name", Row "laniquidar",

"Methyl 6,11-dihydro-11-11-[2-[4-(-2-quinolylmethoxy)phenyl]ethyl]-4-piperidinylidene]-5H-imidazo[2,1-b][3]benzazepine-3-carboxylate" should read

--Methyl 6,11-dihydro-11-[1-[2-[4-(-2-quinolylmethoxy)phenyl]ethyl]-4-piperidinylidene]-5H-imidazo[2,1-b][3]benzazepine-3-carboxylate--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk

P.O. Box 142950

Gainesville, FL 32614-2950

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,790,905

Page 26 of 59

APPLICATION NO.: 10/747,742

DATED : September 7, 2010

INVENTORS : Mark Tawa, Orn Almarsson, Julius F. Remenar

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 159, Table 3,

Column "API Chemical Name", Row "lasofoxifene",

"2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-(4-(2-(1-pyrrolidinyl)ethoxy)phenyl-(5R-cis)-, (5-(R\*, R\*)))-2,3-dihydroxybutanedioate [CAS]" should read

--2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-(4-(2-(1-pyrrolidinyl)ethoxy)phenyl-(5R-cis)-, (S-(R\*, R\*)))-2,3-dihydroxybutanedioate [CAS]--.

Column "API Chemical Name", Row "levamisole",

"Imidazo[2,1-b]thiazole, 2,3,5,6-tetrahydro-6-phenyl-, (5)-[CAS]" should read

--Imidazo[2,1-b]thiazole, 2,3,5,6-tetrahydro-6-phenyl-, (S)- [CAS]--.

Column 160, Table 3,

Column "Example of Therapeutic Use", Row "LAX-111",

"Neuroleptic" should read --Neuroleptic--.

Column 161, Table 3,

Column "API Chemical Name", Row "levetiracetam",

"1-Pyrrolidineacetamide, Alpha-ethyl-2-oxo-, (5)-[CAS]" should read

--1-Pyrrolidineacetamide, Alpha-ethyl-2-oxo-, (S)- [CAS]--.

Column "API Chemical Name", Row "levobupivacaine",

"2-Piperidinecarboxamide, 1-butyl-N-(2,6-dimethylphenyl)-, (5)-[CAS]" should read

--2-Piperidinecarboxamide, 1-butyl-N-(2,6-dimethylphenyl)-, (S)- [CAS]--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk

P.O. Box 142950

Gainesville, FL 32614-2950

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,790,905

Page 27 of 59

APPLICATION NO.: 10/747,742

DATED : September 7, 2010

INVENTORS : Mark Tawa, Orn Almarsson, Julius F. Remenar

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 161, Table 3,

Column "API Chemical Name", Row "levodropropizine",

"1,2-Propanediol, 3-(4-phenyl-1-piperazinyl)-, (5)-[CAS]" should read

--1,2-Propanediol, 3-(4-phenyl-1-piperazinyl)-, (S)- [CAS]--.

Column "API Chemical Name", Row "levofloxacin",

"7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, (5)-[CAS]" should read

--7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, (S)- [CAS]--.

Column "API Chemical Name", Row "levomoprolol",

"2-Propanol, 1-(2-methoxyphenoxy)-3-[(1-methylethyl)amino]-, (5)-[CAS]"

should read

--2-Propanol, 1-(2-methoxyphenoxy)-3-[(1-methylethyl)amino]-, (S)- [CAS]--.

Column "API Chemical Name", Row "levosimendan",

"Propanedinitrile, (14-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono)-, (R)- [CAS]" should read

--Propanedinitrile, [[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]-, (R)-[CAS]--.

Column 163, Table 3,

Column "API Chemical Name, Row "liranaftate",

"Garbamoithioic acid" should read --Carbamoithioic acid--.

Column "API Chemical Name, Row "lisinopril",

"(5)- [CAS]" should read --(S)- [CAS]--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk

P.O. Box 142950

Gainesville, FL 32614-2950



UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,790,905

Page 28 of 59

APPLICATION NO.: 10/747,742

DATED : September 7, 2010

INVENTORS : Mark Tawa, Orn Almarsson, Julius F. Remenar

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 163, Table 3,

Column "API Chemical Name", Row "LLUAlpha",

"S-2,7,8-Trimethyl-6-(11-carboxyethyl)-6-hydroxychroman" should read  
--S-2,7,8-Trimethyl-6-( $\beta$ -carboxyethyl)-6-hydroxychroman--.

Column 164, Table 3,

Row "lobaplatin",

**"Example of**

**Example of Indication"**

**Therapeutic Use**

Anticancer alkylatin

should read

**--Example of**

**Example of Indication--.**

**Therapeutic Use**

Anticancer alkylating

Cancer, lung, small cell

Column 165, Table 3,

Column "API Chemical Name", Row "loratadine",

"1-Pipendinecarboxylic acid" should read  
--1-Piperidinecarboxylic acid--.

Column 167, Table 3,

Column "API Chemical Name", Row "lurtotecan",

"11H-1,4-Dioxino[2,3-g]pyrano[3,4:6,7]indolizino[1,2-b]quinoline-9,12[8H,14H]-dione," should read  
--11H-1,4-Dioxino[2,3-g]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-9,12[8H,14H]-dione,--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk

P.O. Box 142950

Gainesville, FL 32614-2950

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,790,905

Page 29 of 59

APPLICATION NO.: 10/747,742

DATED : September 7, 2010

INVENTORS : Mark Tawa, Orn Almarsson, Julius F. Remenar

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 170, Table 3,

Column "Example of Indication", Row "maribavir",  
"Cancer, pancreatic" should read --Infection, cytomegalovirus--.

Column 171, Table 3,

Column "API Chemical Name", Row "meluadrine",  
"(R\*,R\*)-2,3-dihydroxybutanedioate (1:1) (salt) [CAS]" should read  
--(R\*,R\*)-2,3-dihydroxybutanedioate (1:1) (salt) [CAS]--.

Column 173, Table 3,

Column "API Generic Name", "mepartrncin" should read --mepartricin--.  
Column "API Generic Name", "Methotnmeprazine" should read --Methotrimeprazine--.

Column 175, Table 3,

Row "Methylergonovine",  

<b>"API Chemical Name"</b>	<b>CAS No."</b>	should read	<b>--API Chemical Name</b>	<b>CAS No.--.</b>
			<b>Name</b>	
	113-42-8			113-42-8

Column 177, Table 3,

Column "API Generic Name", "Metnzamide" should read --Metrizamide--.

Column 179, Table 3,

Column "API Chemical Name", Row "misoprostol",  
"Prost-13-en-1-oic acid, 11,16-dihydro 16-methyl-9-oxo-," should read  
--Prost-13-en-1-oic acid, 11,16-dihydroxy-16-methyl-9-oxo-,--.

MAILING ADDRESS OF SENDER:  
Saliwanchik, Lloyd & Eisenschenk  
P.O. Box 142950  
Gainesville, FL 32614-2950

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,790,905

Page 30 of 59

APPLICATION NO.: 10/747,742

DATED : September 7, 2010

INVENTORS : Mark Tawa, Orn Almarsson, Julius F. Remenar

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 183, Table 3,

Column "API Chemical Name", Row "mycophenolate mofetil",  
"4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl," should read  
--4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl,--.

Column 185, Table 3,

Column "API Chemical Name", Row "naltrexone",  
"(SAlpha)-[CAS]" should read --(5Alpha)-[CAS]--.

Column 186, Table 3,

Row "NAMI",

<b>"Example of Therapeutic Use</b> Anticancer, other should read	<b>Example of" Indication</b>
<b>--Example of Therapeutic Use</b> Anticancer, other	<b>Example of--. Indication</b> Cancer, general

Column 187, Table 3,

Column "API Generic Name", "NGX-4016" should read --NCX-4016--.  
Column "API Chemical Name", Row "nicaraven",  
"3-Pyndinecarboxamide, N,N-(1-methyl-1,2-ethanediyl)bis-[CAS]" should read  
--3-Pyridinecarboxamide, N,N'-(1-methyl-1,2-ethanediyl)bis- [CAS]--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk

P.O. Box 142950

Gainesville, FL 32614-2950

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,790,905

Page 31 of 59

APPLICATION NO.: 10/747,742

DATED : September 7, 2010

INVENTORS : Mark Tawa, Orn Almarsson, Julius F. Remenar

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 189, Table 3,

Column "API Chemical Name", Row "nicorandil",

"3-Pyndinecarboxamide" should read --3-Pyridinecarboxamide--.

Column "API Chemical Name", Row "nicotine",

"Pyridine, 3-(1-methyl-2-pyrrolidinyl)-, (5)-[CAS]" should read

--Pyridine, 3-(1-methyl-2-pyrrolidinyl)-, (S)- [CAS]--.

Column "API Chemical Name", Row "niperotidine",

"[(dimethylamino)methyl]furfuryl]thio]ethyl]-2-nitro-N'-piperonyl-1,1-ethenediamine" should read

--N-[2-[[5-[(dimethylamino)methyl]furfuryl]thio]ethyl]-2-nitro-N'-piperonyl-1,1-ethenediamine--.

Column 191, Table 3,

Column "API Chemical Name", Row "NM-3",

"3-(2-methylcarboxymethyl)-6-methoxy-8-hydroxy-isocoumann" should read

--3-(2-methylcarboxymethyl)-6-methoxy-8-hydroxy-isocoumarin--.

Column "API Generic Name",

"N-Methylepinephne" should read --N-Methylepinephrine--.

Column 192, Table 3,

Column "Example of Indication", Row "nitisinone",

"Cirrhosis" should read --Cirrhosis, hepatic--.

Column 193, Table 3,

Column "API Generic Name", "Norelgestramin, Ethinyl Estradial" should read

--Norelgestromin, Ethinyl Estradiol--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk

P.O. Box 142950

Gainesville, FL 32614-2950

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,790,905

Page 32 of 59

APPLICATION NO.: 10/747,742

DATED : September 7, 2010

INVENTORS : Mark Tawa, Orn Almarsson, Julius F. Remenar

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 193, Table 3,

Column "API Generic Name", "Norgestnenone" should read --Norgestrienone--.

Column "API Chemical Name", Row "NV-07",

"2,4,6(1H,3H,5H)-Pyrimidinetrone, 5-ethyl-5-sec-pentyl-, 2-oxime [CAS]"  
should read

--2,4,6(1H,3H,5H)-Pyrimidinetrone, 5-ethyl-5-sec-pentyl-, 2-oxime [CAS]--.

Column 194, Table 3,

Column "Example of Therapeutic Use", Row "NS-220",

"Hypolipaemic/Antitherosclerosis" should read

--Hypolipaemic/Antiatherosclerosis--.

Column 195, Table 3,

Column "API Generic Name", "Octavenne" should read --Octaverine--.

Column "API Chemical Name", Row "octenidine",

"1-Octanamine, N,N-(1,10-decanediyl-di-1(4H)-pyridinyl-4-ylidene)bis-[CAS]"  
should read

--1-Octanamine, N,N'-(1,10-decanediyl-di-1(4H)-pyridinyl-4-ylidene)bis- [CAS]--.

Column "API Chemical Name", Row "olmesartan medoxomil",

"1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-," should read

--1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-,--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk

P.O. Box 142950

Gainesville, FL 32614-2950

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,790,905

Page 33 of 59

APPLICATION NO.: 10/747,742

DATED : September 7, 2010

INVENTORS : Mark Tawa, Orn Almarsson, Julius F. Remenar

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 195, Table 3,

Column "API Chemical Name", Row "omiloxetine",

"Ethanone, 2-[(3R,4S)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-1-piperidinyl]-1-(4-fluorophenyl)-, rel- [CAS]" should read

--Ethanone, 2-[(3R,4S)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-1-piperidinyl]-1-(4-fluorophenyl)-, rel- [CAS]--.

Column 196, Table 3,

Column "Example of Therapeutic Use", Row "Omacor",

"Hypolipaemic/Antitherosclerosis" should read

--Hypolipaemic/Antiatherosclerosis--.

Column 197, Table 3,

Column "API Chemical Name", Row "OPC-51803",

"(5R)-2-[1-(2-chloro-4-(1-pyrrolidinyl)benzoyl)-2,3,4,5-tetrahydro-1H-1-benzazepin-5-yl]-N-isopropylacetamide" should read

--(5R)-2-[1-(2-chloro-4-(1-pyrrolidinyl)benzoyl)-2,3,4,5-tetrahydro-1H-1-benzazepin-5-yl]-N-isopropylacetamide--.

Column "API Chemical Name", Row "Org-12962",

"Piperazine, 1-[6-chloro-5-(trifluoromethyl)-2-pyridinyl]-, monohydrochionde [CAS]" should read

--Piperazine, 1-[6-chloro-5-(trifluoromethyl)-2-pyridinyl]-, monohydrochloride [CAS]--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk

P.O. Box 142950

Gainesville, FL 32614-2950

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,790,905

Page 34 of 59

APPLICATION NO.: 10/747,742

DATED : September 7, 2010

INVENTORS : Mark Tawa, Orn Almarsson, Julius F. Remenar

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 197, Table 3,

Column "API Chemical Name", Row "ornoprostil",

"Prost-13-en-1-oic acid, 11,15-dihydro-17,20-dimethyl-6,9-dioxo-, methyl ester, (11Alpha,13E,15S,17S)-[CAS]" should read

--Prost-13-en-1-oic acid, 11,15-dihydroxy-17,20-dimethyl-6,9-dioxo-, methyl ester, (11Alpha,13E,15S,17S)- [CAS]--.

Column 198, Table 3,

Row "OPC-31260",

**Example of  
Therapeutic Use**  
Unspecified

**Example of**  
**Indication**

should read

**--Example of  
Therapeutic Use**  
Urological

**Example of--.**  
**Indication**  
Unspecified

Column 200, Table 3,

Column "Example of Therapeutic Use", Row "oxandrolone",

"Reproductive/gonad" should read --Reproductive/gonadal, general--.

Column 201, Table 3,

Column "API Generic Name", "Oxypinocemphone" should read --Oxypinocamphone--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk

P.O. Box 142950

Gainesville, FL 32614-2950

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,790,905

Page 35 of 59

APPLICATION NO.: 10/747,742

DATED : September 7, 2010

INVENTORS : Mark Tawa, Orn Almarsson, Julius F. Remenar

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 201, Table 3,

Column "API Chemical Name", Row "palindore",

"2(S)-, (2E)-2-butendioate (1:1)" should read

--2(S)-, (2E)-2-butendioate (1:1)--.

Column "API Chemical Name", Row "palonosetron",

"3a5-2-[(S)-1-Azabicyclo[2.2.2]oct-3-yl]-2,3,3a,4,5,6-hexahydro-1-oxo-1H-benz[de]isoquinoline hydrochloride" should read

--3aS-2-[(S)-1-Azabicyclo[2.2.2]oct-3-yl]-2,3,3a,4,5,6-hexahydro-1-oxo-1H-benz[de]isoquinoline hydrochloride--.

Column 202, Table 3,

Row "PAI inhibs",

**"Example of  
Therapeutic Use  
Antithrombotic**

**Example of"  
Indication**

should read

**--Example of  
Therapeutic Use  
Antithrombotic**

**Example of--.  
Indication  
Thrombosis, venous**

Column 205, Table 3,

Column "API Chemical Name", Row "pentamidine",

"Benzenecarboximidamide, 4,4-[1,5-pentanediy]bis(oxy)]bis-[CAS]" should read

--Benzenecarboximidamide, 4,4'-[1,5-pentanediy]bis(oxy)]bis- [CAS]--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk

P.O. Box 142950

Gainesville, FL 32614-2950



UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,790,905

Page 36 of 59

APPLICATION NO.: 10/747,742

DATED : September 7, 2010

INVENTORS : Mark Tawa, Orn Almarsson, Julius F. Remenar

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 205, Table 3,

Column "API Chemical Name", Row "peplomycin",

"(5)-[CAS]" should read --(S)- [CAS]--.

Column "API Generic Name", "Pencyazine" should --Pericyazine--.

Column 206, Table 3,

Column "Example of Therapeutic Use", Row "pentostatin",

"Anticancer, anticancer, antimetabolite" should read

--Anticancer, antimetabolite--.

Column 207, Table 3,

Column "API Generic Name", "Penmethazine" should --Perimethazine--.

Column "API Chemical Name", Row "perisoxal",

"1-Piperidineethanol, Alpha-(5-phenyl-3-isoxazolyl)-, 2-hydroxy-1,2,3-propanetncarboxylate (2:1) (salt) [CAS]" should read

--1-Piperidineethanol, Alpha-(5-phenyl-3-isoxazolyl)-, 2-hydroxy-1,2,3-propanetricarboxylate (2:1) (salt) [CAS]--.

Column "API Generic Name", "Pertapine" should read --Perlapine--.

Column "API Generic Name", "Permethnn" should read --Permethrin--.

Column "API Generic Name", "PH-b" should read --PH-10--.

Column "API Generic Name", "Phenetunde" should read --Pheneturide--.

Column "API Generic Name", "Phenglutanmide" should read --Phenglutarimide--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk

P.O. Box 142950

Gainesville, FL 32614-2950

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,790,905

Page 37 of 59

APPLICATION NO.: 10/747,742

DATED : September 7, 2010

INVENTORS : Mark Tawa, Orn Almarsson, Julius F. Remenar

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 209, Table 3,

Column "API Generic Name", "Phenopendine" should read --Phenoperidine--.

Column "API Generic Name", "Pholednne" should read --Pholedrine--.

Column "API Generic Name", "pibaserod" should read --piboserod--.

Column "API Generic Name", "Picopenne" should read --Picoperine--.

Column 211, Table 3,

Column "API Chemical Name", Row "pimilprost",

"Acetic acid, [2-[octahydro-5-hydroxy-6-(3-hydroxy-5-methyl-1-nonenyl)-2-pentalenyl]ethoxy]-, methyl ester, [2R-[2Alpha,3Alpha,4Alpha (1E,3S,5S),5β,6aAlpha]]-[CAS]" should read

--Acetic acid, [2-[octahydro-5-hydroxy-6-(3-hydroxy-5-methyl-1-nonenyl)-2-pentalenyl]ethoxy]-, methyl ester, [2R-[2Alpha,3Alpha,4Alpha (1E,3S\*,5S\*),5β,6aAlpha]]- [CAS]--.

Column "API Chemical Name", Row "pioglitazone",

"2,4-Thiazolidinedione, 5-[(4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl)methyl]-, monohydrochlond ( +/- )-[CAS]" should read

--2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl)methyl]-, monohydrochloride (+/-)- [CAS]--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk

P.O. Box 142950

Gainesville, FL 32614-2950

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,790,905

Page 38 of 59

APPLICATION NO.: 10/747,742

DATED : September 7, 2010

INVENTORS : Mark Tawa, Orn Almarsson, Julius F. Remenar

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 213, Table 3,

Column "API Generic Name", "Pipenlate" should read --Piperilate--.

Column "API Generic Name", "pipenne analogues" should read --piperine analogues--.

Column "API Chemical Name", Row "pirmenol",

"(2-Pyndinemethanol, Alpha-[3-(2,6-dimethyl-1-piperidinyl)propyl]-

.Alpha.phenyl-, cis-(+)-[CAS]" should read

--(2-Pyridinemethanol, Alpha-[3-(2,6-dimethyl-1-piperidinyl)propyl]-

.Alpha.phenyl-, cis-(+)- [CAS]--.

Column "API Chemical Name", Row "piroxicam betadex",

"(β-Cyclodextrin" should read --β-Cyclodextrin--.

Column "API Chemical Name", Row "piroxicam cinnamate",

"5,5-dioxide [CAS]" should read --S,S-dioxide [CAS]--.

Column 215, Table 3,

Column "API Generic Name",

"pivampiciiiiin/pivmecillinam" should read --pivampicillin/pivmecillinam--.

Column "API Chemical Name", Row "pivmecillinam",

"[25-(2Alpha,5Alpha,6β)]-[CAS]" should read

--[2S-(2Alpha,5Alpha,6β)]- [CAS]--.

Column 217, Table 3,

Column "API Generic Name",

"Potassium Pemanganate" should read --Potassium Permanganate--.

Column "API Chemical Name", Row "pramipexole",

"(5)- [CAS]" should read --(S)- [CAS]--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk

P.O. Box 142950

Gainesville, FL 32614-2950

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,790,905

Page 39 of 59

APPLICATION NO.: 10/747,742

DATED : September 7, 2010

INVENTORS : Mark Tawa, Orn Almarsson, Julius F. Remenar

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 218, Table 3,

Row "prazosin",

**"Example of  
Therapeutic Use**  
Antihypertensive,

**Example of"**  
**Indication**

should read

**--Example of  
Therapeutic Use**  
Antihypertensive,  
renin system

**Example of--.**  
**Indication**  
Hypertension, general

Column 219, Table 3,

Column "API Chemical Name", Row "pregabalin",

"Hexanoic acid, 3-(aminomethyl)-5-methyl, (5)-[CAS]" should read

--Hexanoic acid, 3-(aminomethyl)-5-methyl, (S)- [CAS]--.

Column "API Chemical Name", Row "Premarin + trimegestone",

"Estra-4,9-dien-3-one, 17-(2-hydroxy-1-oxopropyl)-17-methyl-, [1711 (5)]-[CAS]" should read

--Estra-4,9-dien-3-one, 17-(2-hydroxy-1-oxopropyl)-17-methyl-, [1711 (S)]-[CAS]--.

Column 221, Table 3,

Column "API Generic Name",

"propionyl L-carnitine" should read --propionyl L-carnitine--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk

P.O. Box 142950

Gainesville, FL 32614-2950

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,790,905

Page 40 of 59

APPLICATION NO.: 10/747,742

DATED : September 7, 2010

INVENTORS : Mark Tawa, Orn Almarsson, Julius F. Remenar

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 221, Table 3,

Row "propiverine",

<b>"API Chemical</b>	<b>CAS No."</b>
----------------------	-----------------

<b>Name</b>	
-------------	--

2,2-diphenyl-2-(1-propoxy)	
----------------------------	--

acetic acid	
-------------	--

	60569-19-9
--	------------

(1-methylpiperid-4-yl)	
------------------------	--

ester	54556-98-8
-------	------------

hydrochloride	
---------------	--

should read

<b>--API Chemical</b>	<b>CAS No.--</b>
-----------------------	------------------

<b>Name</b>	
-------------	--

2,2-diphenyl-2-(1-propoxy)	
----------------------------	--

	54556-98-8
--	------------

acetic acid	
-------------	--

	60569-19-9
--	------------

(1-methylpiperid-4-yl)	
------------------------	--

ester hydrochloride	
---------------------	--

Column "API Generic Name", "Propylhexednne" should read --Propylhexedrine--.

Column "API Chemical Name", Row "proxigermanium",

"Propanoic acid, 3,3-(1,3-dioxo-1,3-digermoxanediyl)bis-[CAS]" should read

--Propanoic acid, 3,3'-(1,3-dioxo-1,3-digermoxanediyl)bis- [CAS]--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk

P.O. Box 142950

Gainesville, FL 32614-2950

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,790,905

Page 41 of 59

APPLICATION NO.: 10/747,742

DATED : September 7, 2010

INVENTORS : Mark Tawa, Orn Almarsson, Julius F. Remenar

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 223, Table 3,

Column "API Chemical Name", Row "pseudoephedrine + triprolidine",  
"mixt. with (E)-2-[1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl]pyridine  
monohydrochloride [CAS]" should read  
--mixt. with (E)-2-[1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl]pyridine  
monohydrochloride [CAS]--.

Column "CAS No.", Row "pseudoephedrine",  
"90-82-4, 8054-271, 345-78-8" should read --90-82-4, 8054-27-1, 345-78-8--.

Row "PX-12",

<b>"API Generic Name</b>	<b>API Chemical Name"</b>
PX-12 disulfide	1-Methylpropyl 2-mercaptoimidazolyl

should read

<b>--API Generic Name</b>	<b>API Chemical Name--.</b>
PX-12	1-Methylpropyl 2-mercaptoimidazolyl disulfide

Column "API Generic Name", "Pyinthione" should read --Pyrithione--.

Column "API Generic Name", "Pyronandine" should read --Pyronaridine--.

Column "API Generic Name", "Pyrrolnitnn" should read --Pyrrolnitrin--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk

P.O. Box 142950

Gainesville, FL 32614-2950

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,790,905

Page 42 of 59

APPLICATION NO.: 10/747,742

DATED : September 7, 2010

INVENTORS : Mark Tawa, Orn Almarsson, Julius F. Remenar

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 223, Table 3,

Column "API Chemical Name", Row "quetiapine",

"Ethanol, 2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]-, (E)-2-butenedioate (2:1) (salt) [CAS]" should read

--Ethanol, 2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]-, (E)-2-butenedioate (2:1) (salt) [CAS]--.

Column "API Generic Name", "quinacne" should read --quinacrine--.

Column 224, Table 3,

Column "Example of Indication", Row "quinacrine",

"Creutzfeldt-Jakob disease" should read --Creutzfeldt-Jakob disease--.

Column 225, Table 3,

Column "API Chemical Name", Row "quinaprilat",

"3-Isoquinolinecarboxylic acid, 2-[2-[(1-carboxy-3-phenylpropyl)amino]-1-oxopropyl]-1,2,3,4-tetrahydro-, [3S-[2[R\*(R\*)],3R\*]]-[CAS]" should read

--3-Isoquinolinecarboxylic acid, 2-[2-[(1-carboxy-3-phenylpropyl)amino]-1-oxopropyl]-1,2,3,4-tetrahydro-, [3S-[2[R\*(R\*)],3R\*]]-[CAS]--.

Column "API Chemical Name", Row "ramipril",

"Cyclopenta[b]pyrrole-2-carboxylic acid, 1-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydro-, [2S-[1[R\*(R)],2Alpha,3aβ,6aβ]]-[CAS]" should read

--Cyclopenta[b]pyrrole-2-carboxylic acid, 1-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydro-, [2S-[1[R\*(R\*)],2Alpha,3aβ,6aβ]]-[CAS]--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk

P.O. Box 142950

Gainesville, FL 32614-2950

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,790,905

Page 43 of 59

APPLICATION NO.: 10/747,742

DATED : September 7, 2010

INVENTORS : Mark Tawa, Orn Almarsson, Julius F. Remenar

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 225, Table 3,

Column "API Chemical Name", Row "ranitidine",

"1,1-Ethenediamine, N-[2-([5-[(dimethylamino)methyl]-2-furanyl)methyl]thio]ethyl]-N'-methyl-2-nitro-[CAS]" should read

--1,1-Ethenediamine, N-[2-[[5-[(dimethylamino)methyl]-2-furanyl)methyl]thio]ethyl]-N'-methyl-2-nitro- [CAS]--.

Column "API Chemical Name", Row "ranolazine",

"1-Piperazineacetamide, N-(2,6-dimethylphenyl)-4-(2-hydroxy-3-(2-methoxyphenoxy)propyl)-, (+/-)-[CAS]" should read

--1-Piperazineacetamide, N-(2,6-dimethylphenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]-, (+/-)- [CAS]--.

Column 227, Table 3,

Column "API Generic Name", "raxofeist" should read --raxofelast--.

Column "API Chemical Name", Row "repaglinide",

"Benzoic acid, 2-ethoxy-4-[2-[[3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]amino]-2-oxoethyl]-, (S)-[CAS]" should read

--Benzoic acid, 2-ethoxy-4-[2-[[3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]amino]-2-oxoethyl]-, (S)- [CAS]--.

Column "API Chemical Name", Row "R-flurbiprofen",

"[1,1-Biphenyl]-4-acetic acid, 2-fluoro-Alpha-methyl" should read

--[1,1'-Biphenyl]-4-acetic acid, 2-fluoro-Alpha-methyl--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk

P.O. Box 142950

Gainesville, FL 32614-2950



UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,790,905

Page 44 of 59

APPLICATION NO.: 10/747,742

DATED : September 7, 2010

INVENTORS : Mark Tawa, Orn Almarsson, Julius F. Remenar

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 227, Table 3,

Column "API Generic Name",

"Rho (D) Immune Globuhn (Human)" should read

--Rho (D) Immune Globulin (Human)--.

Column "API Chemical Name", Row "rifaximin",

"[25-(2R\*,16Z,18E,20R\*,22S\*,23S\*,24S\*,25R\*,26S\*,27R\*,28E)]" should read

--[2S-(2R\*,16Z,18E,20R\*,22S\*,23S\*,24S\*,25R\*,26S\*,27R\*,28E)]--.

Column 231, Table 3,

Column "API Chemical Name", Row "ropivacaine",

"2-Piperidinecarboxamide, N-(2,6-dimethylphenyl)-1-propyl-, (5)-[CAS]"

should read

--2-Piperidinecarboxamide, N-(2,6-dimethylphenyl)-1-propyl-, (S)- [CAS]--.

Column "API Chemical Name", Row "rotigotine",

"1-Naphthalenol, 5,6,7,8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-, (5)-[CAS]" should read

--1-Naphthalenol, 5,6,7,8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-, (S)-[CAS]--.

Column 233, Table 3,

Column "API Chemical Name", Row "rubitecan",

"1H-Pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione, 4-ethyl-4-hydroxy-10-nitro-, (5)-[CAS]" should read

--1H-Pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione, 4-ethyl-4-hydroxy-10-nitro-, (S)- [CAS]--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk

P.O. Box 142950

Gainesville, FL 32614-2950

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,790,905

Page 45 of 59

APPLICATION NO.: 10/747,742

DATED : September 7, 2010

INVENTORS : Mark Tawa, Orn Almarsson, Julius F. Remenar

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 235, Table 3,

Column "API Chemical Name", Row "saquinavir",

"Butanediamide, N1-[3-[3-[[1,1-dimethylethyl)amino]carbonyl]octahydro-2(1H)-isoquinoliny]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinoliny]carbonyl)amino]-, [3S-[CAS]" should read

--Butanediamide, N1-[3-[3-[[1,1-dimethylethyl)amino]carbonyl]octahydro-2(1H)-isoquinoliny]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinoliny]carbonyl)amino]-, [3S-[2[1R\*(R\*),2S\*],3Alpha,4aß,8aß]]- [CAS]--.

Column 237, Table 3,

Column "API Chemical Name", Row "Sch-63390",

"7H-Pyrazolo[4,3-e][1,2,4]tnazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-(3-phenylpropyl)-[CAS]" should read

--7H-Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-(3-phenylpropyl)- [CAS]--.

Column "API Generic Name", "SGS technology" should read --SCS technology--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk

P.O. Box 142950

Gainesville, FL 32614-2950

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,790,905

Page 46 of 59

APPLICATION NO.: 10/747,742

DATED : September 7, 2010

INVENTORS : Mark Tawa, Orn Almarsson, Julius F. Remenar

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 237, Table 3,

Row “seratrodist”,

“API Chemical Name	CAS No.”
Benzeneheptanoic acid,	1103187-07-1
zeta-(2,4,5-trimethyl-3,6- dioxo-1,4-cyclohexadien- -yl)-, (+/-)-[CAS]	112665-43-7

should read

--API Chemical Name	CAS No.--.
Benzeneheptanoic acid,	103187-07-1
zeta-(2,4,5-trimethyl-3,6- dioxo-1,4-cyclohexadien- 1-yl)-, (+/-)- [CAS]	112665-43-7

Column “API Chemical Name”, Row “sertindole”,

“2-Imidazolidinone, 1-[2-[4-[5-chloro-1-(4-fluorophenyl)-1H-indol-3-yl]-1-pipendinyl]ethyl]-[CAS]” should read

--2-Imidazolidinone, 1-[2-[4-[5-chloro-1-(4-fluorophenyl)-1H-indol-3-yl]-1-piperidinyl]ethyl]- [CAS]--.

Column 240, Table 3,

Column “Example of Therapeutic Use”, Row “silver sulfadiazine”,

“Anti-infective” should read --Anti-infective, other--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk

P.O. Box 142950

Gainesville, FL 32614-2950

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,790,905

Page 47 of 59

APPLICATION NO.: 10/747,742

DATED : September 7, 2010

INVENTORS : Mark Tawa, Orn Almarsson, Julius F. Remenar

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 239, Table 3,

Column "API Chemical Name", Row "sivelestat",

"Glycine, N-[2-D[4-(2,2-dimethyl-1-oxopropoxy)phenyl]sulfonyl]amino] benzoyl]-[CAS]" should read

--Glycine, N-[2-[[[4-(2,2-dimethyl-1-oxopropoxy)phenyl]sulfonyl]amino] benzoyl]- [CAS]--.

Column 241, Table 3,

Column "API Chemical Name", Row "SN-38",

"(4S)-4,7,11-triethyl-3,4,12,14-tetrahydro-4, 10-dihydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quindin-9-yl" should read

--(4S)-4,7,11-triethyl-3,4,12,14-tetrahydro-4,10-dihydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quindin-9-yl--.

Column "API Chemical Name", Row "soblidotin",

"L-valinamide, N,N-dimethyl-L-valyl-N-[2-methoxy-4-L2-[1-methoxy-2-methyl-3-oxo-3-[(2-phenylethyl)amino]propyl]-1-pyrrolidinyl]-1-(2-methylpropyl)-4-oxobutyl]-N-methyl-, [25-[1[1R\*(R\*),2S\*],2R\*(1S\*,2S\*)]]-[CAS]" should read

--L-valinamide, N,N-dimethyl-L-valyl-N-[2-methoxy-4-[2-[1-methoxy-2-methyl-3-oxo-3-[(2-phenylethyl)amino]propyl]-1-pyrrolidinyl]-1-(2-methylpropyl)-4-oxobutyl]-N-methyl-, [2S-[1[1R\*(R\*),2S\*],2R\*(1S\*,2S\*)]]- [CAS]--.

Column "API Chemical Name", Row "sodium oxybate",

"Butync acid" should read --Butyric acid--.

Column "API Chemical Name", Row "sodium prasterone sulfate",

"3B-hydroxy-5-androsten-17-one(sodium sulfate dihydrate)" should read

--3β-hydroxy-5-androsten-17-one(sodium sulfate dihydrate)--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk

P.O. Box 142950

Gainesville, FL 32614-2950

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,790,905

Page 48 of 59

APPLICATION NO.: 10/747,742

DATED : September 7, 2010

INVENTORS : Mark Tawa, Orn Almarsson, Julius F. Remenar

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 241, Table 3,

Column "API Chemical Name", Row "sofalcone",

"Acetic acid, [5-((3-methyl-2-butenyl)oxy)-2-[3-[4-[(3-methyl-2-butenyl)oxy]phenyl]-1-oxo-2-propenyl]phenoxy]-[CAS]" should read  
--Acetic acid, [5-[(3-methyl-2-butenyl)oxy)-2-[3-[4-[(3-methyl-2-butenyl)oxy]phenyl]-1-oxo-2-propenyl]phenoxy]- [CAS]--.

Column 243, Table 3,

Column "API Chemical Name", Row "SR-146131",

"1H-Indole-1-acetic acid, 2-[[[4-(4-chloro-2,5-dimethoxyphenyl)-5-(2-cyclohexyl)ethyl]-2-thiazolyl]amino]carbonyl]-5,7-dimethyl- [CAS]" should read  
--1H-Indole-1-acetic acid, 2-[[[4-(4-chloro-2,5-dimethoxyphenyl)-5-(2-cyclohexylethyl)-2-thiazolyl]amino]carbonyl]-5,7-dimethyl- [CAS]--.

Column "API Chemical Name", Row "β-aletine",

"Propanamide, N, N(dithiodi-2,1-ethanediyl)bis(3-amino)-[CAS]" should read  
--Propanamide, N, N'(dithiodi-2,1-ethanediyl)bis(3-amino)- [CAS]--.

Column 245, Table 3,

Column "API Generic Name", "Stilbamidine" should read --Stilbamidine--.

Column 247, Table 3,

Column "API Chemical Name", Row "sufentanil",

"Propanamide, N-[4-(methoxymethyl)-1-[2-(2-thienyl)ethyl]-4-pipendinyl]-N-phenyl-[CAS]" should read  
--Propanamide, N-[4-(methoxymethyl)-1-[2-(2-thienyl)ethyl]-4-piperidinyl]-N-phenyl- [CAS]--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk

P.O. Box 142950

Gainesville, FL 32614-2950

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,790,905

Page 49 of 59

APPLICATION NO.: 10/747,742

DATED : September 7, 2010

INVENTORS : Mark Tawa, Orn Almarsson, Julius F. Remenar

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 247, Table 3,

Column "API Chemical Name", Row "sulbenicillin",

"4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-[(phenylsulfoacetyl)amino]-, [2S-[2Alpha,5Alpha,6a(S\*)]]-[CAS]"

should read

--4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-[(phenylsulfoacetyl)amino]-, [2S-[2Alpha,5Alpha,6β(S\*)]]- [CAS]--.

Column "API Generic Name", "Sutfaguanole" should read --Sulfaguanole--.

Column "API Generic Name", "Sutfapyndine" should read --Sulfapyridine--.

Column 249, Table 3,

Column "API Chemical Name", Row "sultamicillin",

"5, 5-dioxide," should read --S, S-dioxide,--.

Column "API Chemical Name", Row "sultopride",

"Benzamide, N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-methoxy-[CAS]" should read

--Benzamide, N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)-2-methoxy-[CAS]--.

Column 251, Table 3,

Column "API Chemical Name", Row "T-1095",

"1-Propanone, 3-(5-benzofuranyl)-1-(2-hydroxy-6-((6-O-methoxycarbonyl)-B-D-glucopyranosyl)oxy)-4-methylphenyl- [CAS]" should read

--1-Propanone, 3-(5-benzofuranyl)-1-(2-hydroxy-6-((6-O-methoxycarbonyl)-β-D-glucopyranosyl)oxy)-4-methylphenyl- [CAS]--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk

P.O. Box 142950

Gainesville, FL 32614-2950

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,790,905

Page 50 of 59

APPLICATION NO.: 10/747,742

DATED : September 7, 2010

INVENTORS : Mark Tawa, Orn Almarsson, Julius F. Remenar

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 251, Table 3,

Column "API Chemical Name", Row "T-1249",

"L-Phenylalaninamide, N-acetyl-L-tryptophyl-L-glutaminy-L-Alpha-glutamyl-L-tryptophyl-L-Alpha-glutamyl-L-glutaminy-L-lysyl-L-isoleucyl-L-threonyl-L-alanyl-L-leucyl-L-leucyl-L-Alpha-glutamyl-L-glutaminy-L-alanyl-L-glutaminy-L-isoleucyl-L-glutaminy-L-glutaminy-L-Alpha-glutamyl-L-lysyl-L-Alpha-glutamyl-asparaginy-L-tyrosyl-L-Alpha-glutamyl-L-leucyl-L-glutaminy-L-lysyl-L-leucyl-L-Alpha-aspartyl-L-lysyl-L-tryptophyl-L-ananyl-L-seryl-L-leucyl-L-tryptophyl-L-Alpha-glutamyl-L-tryptophyl [CAS]"  
should read

--L-Phenylalaninamide, N-acetyl-L-tryptophyl-L-glutaminy-L-Alpha-glutamyl-L-tryptophyl-L-Alpha-glutamyl-L-glutaminy-L-lysyl-L-isoleucyl-L-threonyl-L-alanyl-L-leucyl-L-leucyl-L-Alpha-glutamyl-L-glutaminy-L-alanyl-L-glutaminy-L-isoleucyl-L-glutaminy-L-glutaminy-L-Alpha-glutamyl-L-lysyl-L-Alpha-glutamyl-asparaginy-L-tyrosyl-L-Alpha-glutamyl-L-leucyl-L-glutaminy-L-lysyl-L-leucyl-L-Alpha-aspartyl-L-lysyl-L-tryptophyl-L-ananyl-L-seryl-L-leucyl-L-tryptophyl-L-Alpha-glutamyl-L-tryptophyl- [CAS]--.

Column "API Chemical Name", Row "TA-2005",

"2(1H)-Quinolinone, 8-hydroxy-5-[1-hydroxy-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-, monohydrochloride, [R-(R\*,R\*)]-[CAS]" should read  
--2(1H)-Quinolinone, 8-hydroxy-5-[1-hydroxy-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-, monohydrochloride, [R-(R\*,R\*)]- [CAS]--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk

P.O. Box 142950

Gainesville, FL 32614-2950

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,790,905

Page 51 of 59

APPLICATION NO.: 10/747,742

DATED : September 7, 2010

INVENTORS : Mark Tawa, Orn Almarsson, Julius F. Remenar

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 251, Table 3.

Column "API Chemical Name", Row "TA-993",

"1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-8-methyl-2-(4-methylphenyl)-, (2R,3R)-rel(-)-, (2Z)-2-butenedioate [CAS]" should read

--1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-8-methyl-2-(4-methylphenyl)-, (2R,3R)-rel(-)-, (2Z)-2-butenedioate [CAS]--.

Column "API Chemical Name", Row "tacalcitol",

"9,10-Secachalesta-5,7,10(19)-triene-1,3,24-triol, (1Alpha,3β,5Z,7E,24R)-[CAS]" should read

--9,10-Secocholesta-5,7,10(19)-triene-1,3,24-triol, (1Alpha,3β,5Z,7E,24R)-[CAS]--.

Column "API Chemical Name", Row "tacedinaline",

"Benzamide, 4-(acetylamin)-N-(2-aminophenyl)-[CAS]" should read

--Benzamide, 4-(acetylamin)-N-(2-aminophenyl)- [CAS]--.

Column "API Generic Name", "Tacralimus" should read --Tacrolimus--.

Column "API Chemical Name", Row "tadalafil",

"Pyrazina(1',2':1,6)pyrida(3,4-b)indole1,4-dione, 6-(1,3-benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-, (6R-trans) [CAS]" should read

--Pyrazino(1',2':1,6)pyrido(3,4-b)indole1,4-dione, 6-(1,3-benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-, (6R-trans) [CAS]--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk

P.O. Box 142950

Gainesville, FL 32614-2950



UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,790,905

Page 52 of 59

APPLICATION NO.: 10/747,742

DATED : September 7, 2010

INVENTORS : Mark Tawa, Orn Almarsson, Julius F. Remenar

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 251, Table 3,

Column "API Chemical Name", Row "tafenoquine",

"1,4-Pentanediamine, N4-[2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]-8-quinoliny]- [CAS]" should read  
--1,4-Pentanediamine, N4-[2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]-8-quinoliny]- [CAS]--.

Column "API Generic Name", "taflupaside" should read --tafluposide--.

Column "API Chemical Name", Row "TAK-375",

"(S)-N-[2-(1,6,7,8-Tetrahydro-2H-indeno-[5,4-bifuran-8-yl])propionamide]" should read

--(S)-N-[2-(1,6,7,8-Tetrahydro-2H-indeno-[5,4-b]furan-8-yl)]propionamide--.

Column 253, Table 3,

Column "API Chemical Name", Row "taltirelin",

"L-Prolinamide, N-[(hexahydro-1-methyl-2,6-dioxo-4-pyrimidinyl)carbonyl]-L-histidyl-, (S)-[CAS]" should read  
--L-Prolinamide, N-[(hexahydro-1-methyl-2,6-dioxo-4-pyrimidinyl)carbonyl]-L-histidyl-, (S)- [CAS]--.

Column "API Chemical Name", Row "tamsulosin",

"Benzenesulfonamide, 5-12-[[2-(2-ethoxyphenoxy)ethyl]amino]propyl]-2-methoxy-, (R)-[CAS]" should read

--Benzenesulfonamide, 5-[2-[[2-(2-ethoxyphenoxy)ethyl]amino]propyl]-2-methoxy-, (R)- [CAS]--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk

P.O. Box 142950

Gainesville, FL 32614-2950

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,790,905

Page 53 of 59

APPLICATION NO.: 10/747,742

DATED : September 7, 2010

INVENTORS : Mark Tawa, Orn Almarsson, Julius F. Remenar

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 253, Table 3,

Column "API Chemical Name", Row "tecastemizole",  
"1H-Benzimidazol-2-amine, 1-((4-fluorophenyl)methyl)-N-4-pipendinyl- [CAS]"  
should read

--1H-Benzimidazol-2-amine, 1-((4-fluorophenyl)methyl)-N-4-piperidinyl-  
[CAS]--.

Column 254, Table 3,

Column "Example of Therapeutic Use", Row "talaporfin",  
"Radia/chemosensitizer" should read --Radio/chemosensitizer--.

Column 255, Table 3,

Column "API Chemical Name", Row "tedisamil",  
"Spiro[cyclopentane-1,9-[3,7]diazabicyclo[3.3.1]nonane],  
3',7'-bis(cyclopropylmethyl)-[CAS]" should read

--Spiro[cyclopentane-1,9'-[3,7]diazabicyclo[3.3.1]nonane],  
3',7'-bis(cyclopropylmethyl)- [CAS]--.

Column "API Chemical Name", Row "telbivudine",  
"--β-L-2-deoxythymidine" should read --β-L-2'-deoxythymidine--.

Column "API Chemical Name", Row "telmisartan",  
"(1,1-Biphenyl)-2-carboxylic acid" should read  
--(1,1'-Biphenyl)-2-carboxylic acid--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk

P.O. Box 142950

Gainesville, FL 32614-2950

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,790,905

Page 54 of 59

APPLICATION NO.: 10/747,742

DATED : September 7, 2010

INVENTORS : Mark Tawa, Orn Almarsson, Julius F. Remenar

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 255, Table 3,

Column "API Chemical Name", Row "tenatoprazole",

"1H-Imidazo(4,5-b)pyndine" should read --1H-Imidazo(4,5-b)pyridine--.

Column "API Chemical Name", Row "teniposide",

"Furo[3',4':6,7]naphthol[2,3-d]-1,3-dioxol-6(5aH)-one, 5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-9-[[4,6-O-(2-thienylmethylene)- $\beta$ -D-glucopyranosylloxy]-, [5R-[5Alpha,5a $\beta$ ,8aAlpha,9 $\beta$ (R\*)]]-[CAS]" should read --Furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one, 5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-9-[[4,6-O-(2-thienylmethylene)- $\beta$ -D-glucopyranosyl]oxy]-, [5R-[5Alpha,5a $\beta$ ,8aAlpha,9 $\beta$ (R\*)]]- [CAS]--.

Column 257, Table 3,

Column "API Chemical Name", Row "terfenadine",

"1-Pipendinebutanol, Alpha-[4-(1,1-dimethylethyl)phenyl]-4-(hydroxydiphenylmethyl)-[CAS]" should read

--1-Piperidinebutanol, Alpha-[4-(1,1-dimethylethyl)phenyl]-4-(hydroxydiphenylmethyl)- [CAS]--.

Column "API Chemical Name", Row "terguride",

"Urea, N,N-diethyl-N'-[(8Alpha)-6-methylergolin-8-yl]-[CAS]" should read

--Urea, N,N-diethyl-N'-[(8Alpha)-6-methylergolin-8-yl]- [CAS]--.

Column 259, Table 3,

Column "API Generic Name", "thiacymsenne" should read --thiacymserine--.

Column "CAS No.", Row "Thimerfonate", "5964249" should read --5964-24-9--.

Column "API Generic Name", "Tiadenoi" should read --Tiadenol--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk

P.O. Box 142950

Gainesville, FL 32614-2950

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,790,905

Page 55 of 59

APPLICATION NO.: 10/747,742

DATED : September 7, 2010

INVENTORS : Mark Tawa, Orn Almarsson, Julius F. Remenar

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 259, Table 3,

Column "API Chemical Name", Row "tianeptine",  
"5,5-dioxide [CAS]" should read --S,S-dioxide [CAS]--.

Column 261, Table 3,

Column "API Generic Name", "Tinondine" should read --Tinoridine--.

Column 265, Table 3,

Column "API Chemical Name", Row "travoprost",  
"1-methylethylester (1R(1Alpha(Z),2B(1E,3R\*),3Alpha,5Alpha) [CAS]"  
should read

--1-methylethylester (1R(1Alpha(Z),2B(1E,3R\*),3Alpha,5Alpha) [CAS]--.

Column "API Chemical Name", Row "trazodone",

"1,2,4-Triazolo[4,3-a]pyridin-3(2H)-one, 2-[3-[4-(3-chlorophenyl)-1-  
piperazinylopropyl]- [CAS]" should read

--1,2,4-Triazolo[4,3-a]pyridin-3(2H)-one, 2-[3-[4-(3-chlorophenyl)-1-  
piperazinyl]propyl]- [CAS]--.

Column 269, Table 3,

Column "API Chemical Name", Row "trimipramine",  
"5H-Dibenz[b,f]azepine-5-propanamine, 10,11-dihydro-N,N,t1-trimethyl-, (Z)-2-  
butenedioate (1:1) [CAS]" should read

--5H-Dibenz[b,f]azepine-5-propanamine, 10,11-dihydro-N,N, $\beta$ -trimethyl-, (Z)-2-  
butenedioate (1:1) [CAS]--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk  
P.O. Box 142950

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,790,905

Page 56 of 59

APPLICATION NO.: 10/747,742

DATED : September 7, 2010

INVENTORS : Mark Tawa, Orn Almarsson, Julius F. Remenar

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 269, Table 3,

Column "API Chemical Name", Row "trofosfamide",  
"3-2-(chloroethyl)-2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphonn 2-oxide" should read  
--3-2-(chloroethyl)-2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorin 2-oxide--.

Column 271, Table 3,

Row "Valnoctamide",

<b>"API Chemical Name</b>	<b>CAS No."</b>
4171-13-5	

should read

<b>--API Chemical Name</b>	<b>CAS No.--.</b>
	4171-13-5

Column 271, Table 3,

Column "API Generic Name", "Vaiproic Acid" should read --Valproic Acid--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk  
P.O. Box 142950  
Gainesville, FL 32614-2950

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,790,905

Page 57 of 59

APPLICATION NO.: 10/747,742

DATED : September 7, 2010

INVENTORS : Mark Tawa, Orn Almarsson, Julius F. Remenar

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 272, Table 3,

Row “tyloxapol”,

**“Example of  
Therapeutic Use**  
Formulation, inhalable,  
topical

**Example of”  
Indication**

should read

**--Example of  
Therapeutic Use**  
Formulation, inhalable,  
topical

**Example of--.  
Indication**  
Cystic fibrosis

Column 273, Table 3,

Column “API Chemical Name”, Row “vecuronium”,

“Piperidinium, 1-bis(acetyloxy)-2-(1-piperidinyl)androstan-1 6-yl]-1-methyl-,  
[CAS]” should read

--Piperidinium, 1-[(2 $\beta$ ,3 $\alpha$ ,5 $\alpha$ ,16 $\beta$ ,17 $\beta$ )-3,17-bis(acetyloxy)-2-(1-  
piperidinyl)androstan-16-yl]-1-methyl-, [CAS]--.

Column “API Chemical Name”, Row “venlafaxine”,

“Gyclohexanol, 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]-, [CAS]”

should read

--Cyclohexanol, 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]-, [CAS]--.

Column 275, Table 3,

Column “API Chemical Name”, Row “vinorelbine”,

“C'-Norvincaleukoblastine, 3,4'-didehydro-4'-deoxy-[CAS]” should read

--C'-Norvincaleukoblastine, 3',4'-didehydro-4'-deoxy- [CAS]--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk

P.O. Box 142950

Gainesville, FL 32614-2950

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,790,905

Page 58 of 59

APPLICATION NO.: 10/747,742

DATED : September 7, 2010

INVENTORS : Mark Tawa, Orn Almarsson, Julius F. Remenar

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 275, Table 3,

Column "API Chemical Name", Row "vinpocetine",

"Ebumamenine-14-carboxylic acid, ethyl ester, (3Alpha,16Alpha)-[CAS]"  
should read

--Eburnamenine-14-carboxylic acid, ethyl ester, (3Alpha,16Alpha)- [CAS]--.

Column "API Generic Name", "vonconazole" should read --voriconazole--.

Column 277, Table 3,

Column "API Generic Name", "Yahimbine" should read --Yohimbine--.

Column 278, Table 3,

Row "YT-146",

**"Example of  
Therapeutic Use**  
Anti-inflammation,  
general

**Example of'  
Indication**

should read

**--Example of  
Therapeutic Use**  
Anti-inflammatory

**Example of--.  
Indication**  
Inflammation, general

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk

P.O. Box 142950

Gainesville, FL 32614-2950

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,790,905

Page 59 of 59

APPLICATION NO.: 10/747,742

DATED : September 7, 2010

INVENTORS : Mark Tawa, Orn Almarsson, Julius F. Remenar

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 280, Table 3,

Row "zinc acetate",

**"Example of  
Therapeutic Use**

Antiviral, other  
virus prophylaxis

should read

**--Example of  
Therapeutic Use**

Antiviral, other

**Example of'  
Indication**

**Example of--.  
Indication**

Infection, herpes simplex  
virus prophylaxis

Column 279, Table 3,

Column "API Chemical Name", Row "zolmitriptan",

"(5)-[CAS]" should read --(S)- [CAS]--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Eisenschenk

P.O. Box 142950

Gainesville, FL 32614-2950